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Abstract
Problem/Condition: Although chronic fatigue syndrome (CFS) has been recognized as
a cause of morbidity in the United States, the etiology of CFS is unknown. In addition,
information is incomplete concerning the clinical spectrum and prevalence of CFS in
the United States.
Reporting Period Covered: This report summarizes CFS surveillance data collected in
four U.S. cities from September 1989 through August 1993.
Description of System: A physician-based surveillance system for CFS was estab-
lished in four U.S. metropolitan areas: Atlanta, Georgia; Wichita, Kansas; Grand
Rapids, Michigan; and Reno, Nevada. The objectives of this surveillance system were
to collect descriptive epidemiologic information from patients who had unexplained
chronic fatigue, estimate the prevalence and incidence of CFS in defined populations,
and describe the clinical course of CFS. Patients aged ≥18 years who had had un-
explained, debilitating fatigue or chronic unwellness for at least 6 months were re-
ferred by their physicians to a designated health professional(s) in their area. Those
patients who participated in the surveillance system a) were interviewed by the health
professional(s); b) completed a self-administered questionnaire that included their
demographic information, medical history, and responses to the Beck Depression
Inventory, the Diagnostic Interview Schedule, and the Sickness Impact Profile; c) sub-
mitted blood and urine samples for laboratory testing; and d) agreed to a review of
their medical records. On the basis of this information, patients were assigned to one
of four groups: those whose illnesses met the criteria of the 1988 CFS case definition
(Group I); those whose fatigue or symptoms did not meet the criteria for CFS
(Group II); those who had had an identifiable psychological disorder before onset of
fatigue (Group III); and those who had evidence of other medical conditions that could
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have caused fatigue (Group IV). Patients assigned to Group III were further evaluated
to determine the group to which they would have been assigned had psychological
illness not been present. The epidemiologic characteristics of the illness and the fre-
quency of symptoms among patients were evaluated, and the prevalence and
incidence of CFS were estimated for each of the areas.
Results: Of the 648 patients referred to the CFS surveillance system, 565 (87%) agreed
to participate. Of these, 130 (23%) were assigned to Group I; 99 (18%), Group II;
235 (42%), Group III; and 101 (18%), Group IV. Of the 130 CFS patients, 125 (96%)
were white and 111 (85%) were women. The mean age of CFS patients at the onset of
illness was 30 years, and the mean duration of illness at the time of the interview was
6.7 years. Most (96%) CFS patients had completed high school, and 38% had gradu-
ated from college. The median annual household income for CFS patients was
$40,000. In the four cities, the age-, sex-, and race-adjusted prevalences of CFS for the
4-year surveillance period ranged from 4.0 to 8.7 per 100,000 population. The age-
adjusted 4-year prevalences of CFS among white women ranged from 8.8 to 19.5 per
100,000 population.
Interpretation: The results of this surveillance system were similar to those in pre-
viously published reports of CFS. Additional studies should be directed toward
determining whether the data collected in this surveillance system were subject to
selection bias (e.g., education and income levels might have influenced usage of the
health-care system, and the populations of these four surveillance sites might not be
representative of the U.S. population). 
Actions Taken: In February 1997, CDC began a large-scale, cross-sectional study at
one surveillance site (Wichita) to describe more completely the magnitude and
epidemiology of unexplained chronic fatigue and CFS.
INTRODUCTION
Although chronic fatigue syndrome (CFS) has been recognized as a cause of mor-
bidity in the United States, the etiology of the syndrome is unknown, and only
symptomatic treatments are available. No biologic markers of CFS have been identi-
fied, and no diagnostic tests have been developed; the illness is diagnosed primarily
on the basis of symptoms and signs reported by the patient and exclusion of other
possible causes of prolonged, debilitating fatigue.
Information is incomplete concerning the characteristics of patients who have un-
explained fatigue, their symptoms, and the prevalence of chronic fatigue. Fatigue is a
common complaint, and chronic fatigue is a well-known symptom of many physical
and psychological illnesses (1,2 ). CFS patients constitute a subgroup of persons who
have chronic fatigue.
Outbreaks of similar illnesses were described before the early 1980s (3 ), when in-
terest in endemic CFS was heightened (4 ). Several early reports suggested an
association between the symptoms and Epstein-Barr virus (EBV), and the illness was
referred to as “chronic EBV syndrome” (4–6 ). Subsequent studies indicated that CFS
patients were no more likely than non-CFS patients to have evidence of infection with
EBV (7 ).
In 1988, a CFS case definition was published for the purpose of improving compa-
rability across research studies (8 ). According to this definition, other clinical
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conditions that might have caused the fatigue must have been excluded. At least six
of the following 11 symptoms must have begun at or after the onset of illness and
must have persisted or recurred for at least 6 months: mild fever (37.5–38.6 C [99.5–
101.5 F]) (as measured by the patient) and/or chills; sore throat; painful lymph nodes;
muscular discomfort or myalgia; prolonged (≥24 hours) generalized fatigue after exer-
cise that would have been easily tolerated before the illness; generalized headaches
different from those the patient had before the onset of illness; migratory arthralgia
without joint swelling or redness; neuropsychologic complaints (e.g., photophobia,
transient visual scotomata, forgetfulness, excessive irritability, confusion, difficulty
thinking, inability to concentrate, and depression); sleep disturbance; sudden onset of
symptoms*; and unexplained generalized muscle weakness. Furthermore, unless
eight or more of these symptoms have been present, at least two of the following
three physical signs must have been documented by a physician on at least two occa-
sions and at least 1 month apart: low-grade fever (37.6–38.6 C [99.6–101.5 F]),
nonexudative pharyngitis, and palpable or tender lymph nodes.
Only two peer-reviewed studies have made population-based estimates of the
prevalence of a chronic fatiguing illness. The first study, which was conducted in Aus-
tralia, relied on solicitation of medical-practitioner referrals to identify persons who
had had at least 6 months of unexplained prolonged fatigue accompanied by neu-
ropsychiatric dysfunction (9 ). Using this definition, the researchers estimated the
prevalence as 37 cases per 100,000 population. The second study, which was con-
ducted in the United States, was based on data from a nationwide population-based
mental health survey of 13,000 persons (10 ). This latter study used information ob-
tained by administering the Diagnostic Interview Schedule (DIS) (11 ) to approximate
the CFS case definition. Only one case of CFS was identified, for an estimated preva-
lence of 7.4 cases per 100,000 population.
From September 1989 through August 1993, CDC conducted physician-based sur-
veillance for unexplained chronic fatigue in Atlanta, Georgia; Wichita, Kansas; Grand
Rapids, Michigan; and Reno, Nevada. The primary objectives of this system were to
a) collect descriptive epidemiologic information from patients who had unexplained
chronic fatigue, b) estimate the prevalence and incidence of CFS in defined popula-




Each of the four surveillance sites comprised a central city and its surrounding
counties (12 ). Wichita and Grand Rapids were chosen because they are cities with
stable populations whose overall demographic characteristics approximated those of
the total U.S. population. Reno was selected because of its close proximity to Incline
Village, the site of a 1986 cluster of CFS cases (4 ). Atlanta was chosen because of the
proximity to CDC for special laboratory studies.
*This factor is not a symptom, but it is considered to be of equal importance as the symptoms
for the purposes of the CFS case definition (8 ).
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Surveillance System Procedures
At each surveillance site, physicians whose clientele were likely to include patients
who have CFS (i.e., family practitioners, internists, infectious disease specialists, and
rheumatologists) were identified by using telephone and medical directories. Of the
eligible physicians, 879 were asked to participate in the study; 409 (47%) of these phy-
sicians agreed to participate. The site-specific participation rates were 55% in both
Wichita and Reno, 45% in Grand Rapids, and 37% in Atlanta (12 ). The participating
physicians were contacted annually to confirm their continued participation and were
sent periodic newsletters to inform them of the status of the surveillance system.
Two surveillance nurses were designated in each of the four cities. Patients who
possibly had CFS were referred by the participating physicians to the surveillance
nurses based in that city. Physicians were asked to refer patients aged ≥18 years who
had had at least 6 months of unexplained debilitating fatigue or chronic unwellness.
Debilitating fatigue was defined as the patient’s subjective report of reduced activity
level and greater effort required to perform the same routine activities as were per-
formed before onset of fatigue. Chronic unwellness was defined as a patient’s report
of two or more of the following symptoms occurring at least monthly: fever, sore
throat, unusual muscle weakness, unusual fatigue after exercise, tender lymph nodes,
myalgia, and arthralgia.
Those patients who participated in the surveillance system a) were interviewed by
at least one of the surveillance nurses in their city, b) completed a self-administered
questionnaire, c) submitted blood and urine samples for laboratory testing, and
d) agreed to a review of their medical records. The self-administered questionnaire
included the patient’s demographic information (i.e., self-reported age, race/ethnicity,
sex, household income, and educational level), medical history, and responses to the
Beck Depression Inventory (BDI) (13 ) (i.e., to measure the symptoms of depression)
and the Sickness Impact Profile (SIP) (14 ) (i.e., to measure the effects of fatiguing
illness on daily activities, attitudes, and behaviors).
During the personal interview, the surveillance nurse(s) obtained informed consent
from each participant; reviewed the self-administered questionnaire with the patient;
and obtained information concerning the onset, frequency, and severity of all symp-
toms reported by the patient, including symptoms not included in the CFS case
definition, self-reported energy levels, and ability to perform everyday activities. Cog-
nitive function was measured by tests of memory, attention, and concentration. The
DIS (11 ) was administered to identify those patients who had psychological illnesses.
Only the DIS sections concerning somatization, panic disorder, generalized anxiety
disorder, and depression were used.
For each patient, a battery of standard blood and urine tests was performed, includ-
ing a complete blood count, urinalysis, and renal analyses and measurements of
erythrocyte sedimentation rate, thyroid function, and liver function. The surveillance
nurses reviewed for each patient the medical records maintained by the referring phy-
sician and summarized the information regarding the symptoms suggestive of CFS,
the laboratory test results, other illnesses and health problems, and hospitalizations.
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Classification of Participating Patients
A physician review committee (PRC), composed of clinicians and researchers, was
established for the purpose of classifying the participating patients into one of four
groups (Figure 1). The assignment of each patient into one of these groups was de-
cided by at least three members of the PRC and was based on an independent review
of the summarized information for each patient. The PRC reviewers unanimously
agreed on the initial classification of 82% of all cases reviewed. When the initial clas-
sification was not unanimous, PRC members conferred and reached a consensus.
CDC then compiled and analyzed the data for each group of patients.
The 1988 case definition of CFS (8 ) was used as the basis for classification of pa-
tients. Patients whose illnesses met the criteria of the CFS case definition (i.e., the CFS
patients) were assigned to Group I. Patients whose fatigue or symptoms did not meet
the criteria for CFS were assigned to Group II. Patients who had evidence of a psycho-
logical disorder that was diagnosable before the onset of fatigue and that could have
explained the fatiguing illness were assigned to Group III. Patients in this group were
further evaluated to determine the group to which they would have been assigned had
psychological illness not been present (i.e., Groups III-I, III-II, or III-IV). Patients who




During the 4-year surveillance period from September 1989 through August 1993,
participating physicians referred 648 patients who had had unexplained debilitating
fatigue or chronic unwellness for at least 6 months. Of these, 565 (87%) patients
agreed to participate in the surveillance system, and 83 (13%) declined. The largest
percentage of participants was from Atlanta (46%), followed by Wichita (22%), Reno
(18%), and Grand Rapids (14%) (Table 1).
Characteristics and Classification of Participants
Of the 565 patients, 130 (23%) were assigned to Group I; 99 (18%), Group II;
235 (42%), Group III; and 101 (18%), Group IV (Table 1). The distribution of patients by
group was similar for all four surveillance sites. The demographic characteristics of
patients did not differ significantly by group (Table 2). Most Group I patients were
white (96%) and female (85%) and had a median of 14 years of education and a me-
dian annual household income of $40,000. The mean age at onset of fatigue for
Group I patients was 30 years (range: 15–56 years), and the mean age at the time of
the interview was 37 years, resulting in a mean illness duration of 6.7 years.
Symptoms and Signs
Each symptom and sign listed in the CFS case definition was evaluated to deter-
mine the frequency with which it was reported by patients. Each symptom was
reported by at least 73% of the 130 Group I patients. However, only 48 (37%) Group I
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swollen lymph nodes, sleep
disturbance, muscle weakness,
unusual fatigue, or sudden onset
*Atlanta, Georgia; Wichita, Kansas; Reno, Nevada; and Grand Rapids, Michigan.
FIGURE1. Use of the 1988 case definition for chronic fatigue syndrome (CFS) to
classify participants in the CFS surveillance system, by diagnostic category — four
U.S. cities,* September 1989 through August 1993
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patients reported that the onset of their symptoms occurred suddenly (i.e., in
<24 hours) (Table 3), and only seven (5%) Group I patients were classified as such on
the basis of this criterion in combination with other symptoms and signs. In addition,
≤32% of Group I patients had documented physical criteria that met the CFS case defi-
nition.
Symptoms and signs were reported least frequently by Group II patients, although
this directly reflected the definition for assignment to this group. Persons who had
psychological or medical conditions that possibly explained the fatigue (Groups III and
IV, respectively) reported having had more symptoms and signs of CFS than patients
in Group II, but fewer symptoms and signs than patients in Group I. Patients assigned
to Groups III-I, III-II, and III-IV reported frequencies of symptoms remarkably similar to
those of patients in Groups I, II, and IV, respectively.
Symptoms not included in the CFS case definition that were reported by pa-
tients included shortness of breath, cough, wheezing, nausea, vomiting, constipation,
diarrhea, stomach ache, bloating, ringing in the ears, numbness, poor balance, anger,
anxiousness, nightmares, night sweats, chest pain, heart palpitations, itchiness, and
skin rashes. No one symptom or group of symptoms was reported by >50% of respon-
dents. Group I patients most often reported symptoms not included in the case
definition, followed by patients in Groups III and IV; patients in Group II reported such
symptoms least often.
Prevalence
On the basis of 1990 U.S. census data for the counties encompassing each study
site, the crude 4-year period prevalence of CFS among persons aged ≥18 years ranged
from 3.8 cases per 100,000 population in Atlanta to 9.6 per 100,000 in Wichita, with an
overall crude rate of 5.2 per 100,000 (Table 4). The differences in prevalence between
the surveillance sites remained after directly adjusting for age, sex, and race.
Because most patients who had CFS were white (98%) and female (85%), the site-
specific period prevalences were calculated for this group. For white women, the
TABLE 1. Distribution of patients* participating in the chronic fatigue syndrome (CFS)






Group I Group II Group III Group IV
No. % No. % No. % No. %
Atlanta, GA 61 (23.6) 48 (18.5) 101 (39.0)  49 (18.9) 259
Grand Rapids, MI 22 (27.5) 12 (15.0)  36 (45.0)  10 (12.5)  80
Reno, NV 19 (19.0) 17 (17.0)  48 (48.0)  16 (16.0) 100
Wichita, KS 28 (22.2) 22 (17.5)  50 (39.7)  26 (20.6) 126
Total 130 (23.0) 99 (17.5) 235 (41.6) 101 (17.9) 565
*Persons aged ≥18 years.
†Patients were assigned to one of four groups: those whose illnesses met the criteria of the
1988 CFS case definition (Group I); those whose fatigue or symptoms did not meet the criteria
for CFS (Group II); those who had had an identifiable psychological disorder before onset of
fatigue (Group III); and those who had evidence of a medical condition that could have caused
fatigue (Group IV).
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crude prevalence rates ranged from 8.6 cases per 100,000 population in Atlanta to
17.7 per 100,000 in Wichita, with an overall crude rate of 10.8 per 100,000 (Table 4).
The overall crude prevalence rate for white men was 2.1 per 100,000. Estimates of
site-specific prevalence rates for persons of other racial/ethnic groups were not calcu-
lated because of the small number of cases.
The estimated prevalence of unexplained chronic fatigue was based on the 393 pa-
tients who did not have evidence of a medical condition that could have caused
fatigue (i.e., patients in Groups I and II and patients in Group III who did not have a
medical exclusion). The crude period prevalence of chronic fatigue ranged from
12.9 per 100,000 population in Atlanta to 34.3 per 100,000 in Wichita, with an overall
TABLE 2. Demographic characteristics of patients* participating in the chronic fatigue
syndrome (CFS) surveillance system, by diagnostic category† — four U.S. cities,§












No. % No. % No. % No. % No. %
Sex
Female 111 (85) 77 (78) 193 (82) 78 (77) 459 (81)
Male  19 (15) 22 (12)  42 (18) 23 (13) 106 (19)
Race
White 125 (96) 97 (99) 222 (94) 93 (95) 537 (97)
Other   5 ( 2)  2 ( 1)  13 ( 6) 18 ( 5)  28 ( 3)
Level of education
Less than high school
 diploma   3 ( 2)  5 ( 5)   9 ( 4)  3 ( 3)  20 ( 4)
High school diploma  18 (14) 10 (10)  30 (13) 15 (15)  73 (13)
Some college and/or
technical school  59 (45) 40 (41) 101 (45) 39 (39 239 (44)
College degree
or greater  50 (38) 43 (44)  83 (37) 41 (41) 217 (40)
Annual household
income
<$20,000  23 (15)  9 ( 9)  52 (22) 12 (12)  96 (17)
$20,000–$50,000  55 (42) 48 (48) 103 (44) 46 (46) 252 (45)
>$50,000  42 (32) 37 (37)  57 (24) 37 (37) 173 (31)
Mean age at onset of
fatigue (yrs) 30 32 35 38 34
Mean age at time of
interview (yrs) 37 38 41 44 40
Mean duration of
illness (yrs) 6.7 6.3 5.8 5.8 6.1
*Persons aged ≥18 years.
†Totals may not add up to 100% because of differences in response rates. Patients were assigned
to one of four groups: those whose illnesses met the criteria of the 1988 CFS case definition
(Group I); those whose fatigue or symptoms did not meet the criteria for CFS (Group II); those
who had had an identifiable psychological disorder before onset of fatigue (Group III); and
those who had evidence of a medical condition that could have caused fatigue (Group IV).
§Atlanta, Georgia; Wichita, Kansas; Grand Rapids, Michigan; and Reno, Nevada.
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rate of 18.4 per 100,000 (Table 5). As with the CFS prevalence differences among sites,
the differences in prevalence of chronic fatigue remained after adjustment, using 1990
U.S. census data, for sex, race, and age. For white women, the crude prevalence rate
of unexplained chronic fatigue ranged from 28.6 cases per 100,000 population in
Atlanta to 60.0 per 100,000 in Wichita, with an overall prevalence of 37.3 per 100,000.
The overall crude prevalence rate of chronic fatigue for white men was 7.0 cases per
100,000. The rank orders of prevalence of CFS and unexplained chronic fatigue for the
four surveillance sites were the same using both crude and the adjusted rates.
Incidence
An incident case was defined as a case of CFS in a patient (i.e., illness in a patient
assigned to Group I) who had onset of symptoms during the 4-year surveillance
period. Only 19 incident cases were identified: 10 in Atlanta, four in Wichita, four in
Grand Rapids, and one in Reno. The overall annual incidence rates, as well as the
site-specific annual incidence rates, were less than one case per 100,000 persons. The
rates of CFS for the four surveillance sites were not significantly different, and the
rates remained stable during the 4-year surveillance period.
TABLE 3. Percentage of patients* participating in the chronic fatigue syndrome (CFS)
surveillance system who reported CFS symptoms and signs, by diagnostic category†
— four U.S. cities,§ September 1989 through August 1993
Symptoms/Signs
Diagnostic category           
Group I Group II Group III Group IV Total
Symptoms
Neurocognitive complaints 98 87 96 92 95
Fever and/or chills 96 61 80 76 80
Sore throat 92 41 68 71 69
Myalgia 88 58 80 75 78
Sleep disturbance 92 61 84 83 81
Muscle weakness 88 55 75 70 74
Swollen lymph nodes 84 33 62 65 62
Unusual fatigue 81 37 64 67 64
Arthralgia 81 37 66 62 64
Headache 73 35 60 60 59
Sudden onset 37 22 29 44 32
Signs
Palpable lymph nodes 32 17 16 17 20
Nonexudative pharyngitis 24 15 12 15  6
Fever  5  2  4  4  4
*Persons aged ≥18 years.
†Patients were assigned to one of four groups: those whose illnesses met the criteria of the
1988 CFS case definition (Group I); those whose fatigue or symptoms did not meet the criteria
for CFS (Group II); those who had had an identifiable psychological disorder before onset of
fatigue (Group III); and those who had evidence of a medical condition that could have caused
fatigue (Group IV).
§Atlanta, Georgia; Wichita, Kansas; Grand Rapids, Michigan; and Reno, Nevada.
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DISCUSSION
This surveillance system demonstrated the feasibility of conducting surveillance
for an illness characterized primarily on the basis of self-reported symptoms. This sys-
tem identified the existing CFS cases in those patients who were referred to the
system at the four surveillance sites. The annual number of CFS incident cases did not
increase during the surveillance period.
The mean age of the CFS patients at the time of symptom onset, 30 years, was
similar to that reported previously (9,12 ). The 6.7-year average duration of fatiguing
illness before participation in this surveillance system was consistent with the re-
ported long-term nature of CFS (15 ). Less than 8% of the CFS patients reported an
eventual absence of all symptoms during the surveillance period. If recovery from CFS
is reflected by the absence of symptoms, then the 4-year period prevalence estimates
should provide an estimate of point prevalence for August 31, 1993 (i.e., the last day
of the surveillance period).
The results of several previously published studies indicated that CFS occurs pri-
marily among white females (12,15,16 ), and the high percentage of CFS patients who
were white women in the CDC surveillance system for CFS was consistent with these
TABLE 4. Prevalence rates* of chronic fatigue syndrome — four U.S. cities, September




City Crude Adjusted† Crude Adjusted§
Atlanta, GA 3.8 4.0  8.6  8.8
Grand Rapids, MI 6.1 6.3 10.7 11.9
Reno, NV 7.4 6.7 14.1 15.3
Wichita, KS 9.6 8.7 17.7 19.5
Total 5.2 6.4 10.8 13.9
*Prevalence rates for the 4-year period per 100,000 persons aged ≥18 years.
†Adjusted for age, race, and sex.
§Adjusted for age.
TABLE 5. Prevalence rates* of chronic fatiguing illness† — four U.S. cities, September




City Crude Adjusted§ Crude Adjusted¶
Atlanta, GA 12.9 13.7 28.6 29.1
Grand Rapids, MI 19.5 18.6 36.1 39.7
Reno, NV 32.6 29.1 57.3 60.3
Wichita, KS 34.3 31.4 60.1 65.7
Total 18.4 23.2 37.3 48.7
*Prevalence rates for the 4-year period per 100,000 persons aged ≥18 years.
†Includes persons who have chronic fatigue syndrome.
§Adjusted for age, race, and sex.
¶Adjusted for age.
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reports. Previous reports also indicated that persons who have CFS are more likely to
be well-educated and are potentially high-income earners (12,15,16 ). Of the CFS pa-
tients identified by the surveillance system, 96% had graduated from high school, and
38% of this group had graduated from college. Although 48% of CFS patients were
unemployed at the time of interview, the median annual household income of these
patients was $40,000. However, the higher prevalence of CFS among some groups in
this study (e.g., white women) could reflect selection biases. For example, the educa-
tion and income levels of the patients participating in the surveillance system could
have influenced their pattern of using the health-care system (i.e., persons with lower
incomes who had a fatiguing illness might not have sought medical care for the illness
and would not have been referred to the surveillance system).
The number and pattern of symptoms reported by patients in Groups I, III, and IV
were similar, suggesting that the criteria of the CFS case definition do not enable clini-
cians to reliably distinguish which patients have a history of a psychological disorder.
The National Institutes of Health (17 ) and CDC (18 ) have recommended that future
studies of fatiguing illness continue to include patients both with and without a history
of a psychological disorder so that information regarding these groups can be ana-
lyzed separately.
The physical signs listed in the CFS case definition were not useful for classifying
CFS cases. Only seven (5%) of the CFS cases were classified as such based on the
presence of physical signs. Furthermore, no specific symptom or group of symptoms
enabled CFS to be distinguished from illness in patients assigned to the other groups.
Illnesses in Group I patients might represent one end of a CFS spectrum (i.e., the most
severe degree of illness), whereas illnesses in Group II patients might represent the
other end (i.e., the least severe). By definition, the Group II patients reported fewer
CFS symptoms, but this group also reported substantially fewer symptoms not in-
cluded in the CFS case definition.
The crude estimates of the 4-year period prevalence of CFS ranged from 3.8 to
9.6 cases per 100,000 population. These estimates could not be compared with the
prevalence of 7.4 per 100,000 reported previously (10 ) because this latter estimate
a) was based on an approximation to the CDC CFS case definition and b) represented
a lifetime prevalence. Because of the long duration of CFS, the period prevalence
estimates derived from the CDC surveillance system can be more appropriately com-
pared with the point prevalence estimates derived from the study conducted in
Australia (9 ). Although the overall period prevalence estimate of CFS in the four U.S.
cities (i.e., 5.2 cases per 100,000 population) was lower than the point prevalence esti-
mate reported for the study in Australia (37.1 per 100,000), the CFS case definition
used in the CDC surveillance system was more restrictive. The CDC classification for
unexplained chronic fatigue more closely approximated the CFS case definition used
in the study conducted in Australia (19 ), and the site-specific period prevalence esti-
mates of unexplained chronic fatigue in the four U.S. cities (i.e., 11.3–27.8 cases per
100,000 population) were comparable to the point prevalence estimate of CFS derived
from the study conducted in Australia (9 ).
Reno was chosen as a surveillance site because of its close proximity to Incline
Village (i.e., the site of the first CDC investigation of a cluster of CFS cases) and
because of concern regarding the incidence of CFS in this geographic area (4 ). The
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prevalence of CFS in Reno, however, was similar to the prevalence in the other surveil-
lance sites, and the incidence of CFS in this area was the lowest among the sites.
This CFS surveillance system demonstrated the feasibility of collecting information
concerning the demographic characteristics of participants and estimating a 4-year
period prevalence for both CFS and unexplained prolonged fatigue. However, the pos-
sible underascertainment of CFS cases in this study may have biased these estimates
downward; all the estimated rates should, therefore, be considered minimum esti-
mates of the true prevalence of CFS and unexplained chronic fatigue in the four U.S.
cities.
At least six factors could have been associated with underreporting of CFS cases.
First, some physicians who treat patients who have CFS might not have been asked to
participate in the surveillance system. However, current telephone and medical direc-
tories were used to identify such physicians, and all these physicians were contacted
and asked to participate in the surveillance system. In addition, physicians who were
identified during the surveillance period were asked to participate, and contact was
maintained with participating physicians during the surveillance period to encourage
continued participation. Second, approximately 50% of all physicians who were asked
to participate chose not to do so; however, most of these physicians reported that they
either a) did not provide service to patients who have CFS or b) did not accept CFS as
an established diagnosis. Third, follow-up surveys of the 489 participating physicians
indicated that, of the 241 physicians who provided service to patients who should
have been referred to the surveillance system, 22 (9%) physicians did not refer such
patients. Fourth, participating physicians might have referred only those patients
whose illness was probably CFS, rather than all patients whose illness met the screen-
ing criteria (i.e., >67% of patients reported that their illness had been diagnosed as
CFS by the physician before the referral). Fifth, 13% of the patients who had been
referred to the surveillance system chose not to participate. Finally, many patients
who had a fatiguing illness might not have sought medical care; however, a CDC sur-
vey conducted in 1994 indicated that 82% of persons who had unexplained chronic
fatigue sought medical care for the illness (CDC, unpublished data). All these factors
could have contributed to an underestimation of the prevalence of CFS and unex-
plained chronic fatigue in the four surveillance sites. However, these prevalence
estimates, even if understated, are similar to previously reported estimates (9 ).
The sites chosen for this surveillance system were not selected randomly; there-
fore, the findings cannot be directly generalized to the overall U.S. population. The
range of prevalence estimates for the four sites might reflect actual differences be-
tween the sites or differences in case ascertainment. An additional limitation of this
surveillance system was the potential for inaccurate recall of information by patients,
whose average illness duration at the time of interview was >6 years. However, many
patients kept extensive records of their fatiguing illness and were able to provide de-
tailed information regarding the onset of symptoms. Future studies of CFS should
include patients who have more recent onset of illness to minimize the potential for
recall bias.
Despite the limitations, this surveillance system will assist in investigations of
CFS and its impact on patients who have the illness. In February 1997, CDC began a
large-scale, cross-sectional study at one surveillance site (Wichita) to describe more
completely the magnitude and epidemiology of CFS. The population-based approach
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will enable investigators to actively and more completely identify patients who have
CFS and unexplained chronic fatigue. Information concerning these patients can then
be compared with information for persons in the same population who do not have
chronic fatigue.
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Abstract
Problem/Condition:  Despite the widespread availability of a safe and effective vac-
cine against tetanus, 201 cases of the disease were reported during 1991–1994. Of
patients with known illness outcome, the case-fatality rate was 25%.
Reporting Period Covered:  1991–1994.
Description of System:  Physician-diagnosed cases of tetanus are reported to local
and state health departments, the latter of which reports these cases on a weekly basis
to CDC’s National Notifiable Disease Surveillance System. Since 1965, state health de-
partments also have submitted supplemental clinical and epidemiologic information
to CDC’s National Immunization Program.
Results:  During 1991–1994, 201 cases of tetanus were reported from 40 states, for an
average annual incidence of 0.02 cases per 100,000 population. Of the 188 patients for
whom age was known, 101 (54%) were aged ≥60 years and 10 (5%) were aged
<20 years. No cases of neonatal tetanus were reported. Among adults, the risk for
tetanus increased with age; the risk for persons aged ≥80 years was more than
10 times greater than the risk for persons aged 20–29 years. All deaths occurred
among persons aged ≥30 years. The case-fatality rate (overall: 25%) increased with
age, from 11% in persons aged 30–49 years to 54% in persons aged ≥80 years. Only
12% of all patients were reported to have received a primary series of tetanus toxoid
before onset of illness. For 77% of patients, tetanus occurred after an acute injury was
sustained. Of patients who obtained medical care for their injury, only 43% received
tetanus toxoid as part of wound prophylaxis.
Interpretation:  The epidemiology of reported tetanus in the United States during
1991–1994 was similar to that during the 1980s. Tetanus continued to be a severe
disease primarily of older adults who were unvaccinated or inadequately vaccinated.
Most tetanus cases occurred after an acute injury was sustained, emphasizing the
need for appropriate wound management.
Actions Taken:  In addition to decennial booster doses of tetanus-diphtheria toxoid
during adult life, the Advisory Committee on Immunization Practices (ACIP) recom-
mends vaccination visits for adolescents at age 11–12 years and for adults at age
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50 years to enable health-care providers to review vaccination histories and adminis-
ter any needed vaccine. Full implementation of the ACIP recommendations should
virtually eliminate the remaining tetanus burden in the United States.
INTRODUCTION
The reported incidence of tetanus has declined substantially since the mid-1940s,
when tetanus toxoid (TT) became available for widespread use (1,2 ). This decline
in tetanus incidence followed a) the widespread use of both tetanus toxoid (TT)-
containing vaccines formulated as diphtheria and tetanus toxoids and whole-cell per-
tussis vaccine (DTP) and diphtheria and tetanus toxoids (DT) for infants and children
and diphtheria and tetanus toxoid (Td) for adults, b) the use of TT and tetanus immune
globulin (TIG) for postexposure prophylaxis in wound treatment, and c) improved
wound care and management. Furthermore, the proportion of the U.S. population
residing in urban areas has increased during the 1900s (3 ), resulting in decreased
exposure to tetanus spores; this decreased exposure possibly contributed to the de-
cline in tetanus mortality.
Major efforts have been made to increase immunization coverage among children
in the United States. All 50 states have passed legislation requiring that children be
vaccinated for tetanus before admission to school (4 ), and >96% of school-aged chil-
dren have received three or more DTP vaccinations by the time they begin school (1 ).
Vaccination rates historically have been lower for preschool children aged <5 years
(1,4 ). Since 1991, initiatives to improve immunization coverage among preschool chil-
dren have substantially increased immunization levels among 2-year-old children (5 ).
In 1994, 93% of children aged 19–35 months had been vaccinated with three doses of
either DTP or pediatric DT (6 ). Vaccination coverage among elderly persons remains
low (7 ).
CDC conducts surveillance for tetanus to monitor the epidemiology of the disease
and to identify persons at greatest risk. This report describes an analysis of reported
tetanus cases in the United States for 1991–1994 and evaluates long-term trends of
disease incidence since 1947.
METHODS
Tetanus Surveillance
Tetanus surveillance relies on the passive reporting of physician-diagnosed cases
to local and state health departments. Because a laboratory assay to enable a defini-
tive diagnosis of tetanus is not routinely available, the diagnosis is based on the
clinical judgment of the attending physician.  Before 1990, the clinical case definition
of tetanus was “physician-diagnosed tetanus.” In 1990, this definition was revised, for
the purposes of public health surveillance, to include illness characterized by an acute
onset of hypertonia and/or painful muscular contractions (usually of the muscles of
the jaw and neck) and generalized muscle spasms without other apparent medical
cause (8 ).
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State health departments report cases of tetanus on a weekly basis to CDC’s
National Notifiable Disease Surveillance System (NNDSS). CDC publishes the number
of cases reported by each state to the NNDSS on a weekly basis and in an annual
summary (2 ). In addition, state health departments report supplemental clinical and
epidemiologic information for each case to CDC’s National Immunization Program
(NIP). This supplemental reporting system, which was initiated in 1965, provides
CDC with information concerning the clinical history, presence and nature of any
associated risk factors, vaccination status of the patient, wound care, and clinical man-
agement for each tetanus case (9 ). A summary of this additional information is
published every 2–3 years (10–13 ).
Data Analysis
The differences between medians were tested by using the Wilcoxon rank sum test
statistic (14 ). A p-value of <0.05 was considered statistically significant.
RESULTS
Long-Term Trends
The national tetanus surveillance system documented a decrease in tetanus
morbidity from 560 reported cases in 1947 (i.e., the year national reporting of tetanus
cases was initiated) to fewer than 50 cases in both 1992 and 1993 (Figure 1). However,
since 1976, the rate of decline of reported tetanus incidence has been slower. The inci-
dence rate for 1991–1994 was similar to that for 1987–1990. The overall case-fatality
rate also has declined, from 91% in 1947 to 44% in 1976 and to 24% in 1989–1990.
Since 1990, the overall case-fatality rate has remained relatively unchanged (i.e., 25%
overall for 1991–1994).
Epidemiology
During 1991–1994, 201 tetanus cases were reported to the NNDSS (i.e., 57 cases in
1991, 45 in 1992, 48 in 1993, and 51 in 1994). The average annual incidence rate for
1991–1994 was 0.02 cases per 100,000 population; this rate represents a 95% decrease
from the 0.39 cases per 100,000 population reported for 1947.
At least one case of tetanus was reported by each of 39 states and the District of
Columbia during 1991–1994 (Figure 2), and tetanus cases were reported all 4 years by
eight states (California, Florida, Illinois, Michigan, Minnesota, Ohio, Pennsylvania, and
Texas). No cases were reported in 11 states; six (55%) of these states are located in the
Rocky Mountain and West North Central regions (i.e., regions in which the reported
incidence of tetanus was low in previous years [10–13 ]).
Supplemental information was provided for 192 (96%) of the 201 reported tetanus
cases. Of the 189 patients for whom sex was reported, 99 (52%) were female. Of
188 patients for whom age was reported, 101 (54%) were aged ≥60 years, and 10 (5%)
were aged <20 years (Figure 3). Six cases occurred in children aged <15 years. No
cases of neonatal tetanus were reported. The youngest patient was an unvaccinated
6-year-old boy who had sustained a puncture wound in his foot. He had generalized







































*Cases were reported from 39 states and the District of Columbia.
FIGURE 2. Reported number of tetanus cases, by state — United States,* 1991–1994
































Tetanus cases, by year — United States, 1980–1994
FIGURE 1. Reported number of tetanus cases, by year — United States, 1947–1994
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tetanus that required mechanical ventilation; he recovered after a 1-month hospitali-
zation.
A total of 46 deaths occurred among the 185 patients whose illness outcome was
known (case-fatality rate: 25%). All tetanus-related deaths occurred among persons
aged ≥30 years. The case-fatality rate increased with age, from 11% in persons aged
30–49 years to 54% in persons aged ≥80 years.
Type of Tetanus
The type of tetanus was reported for 150 cases. Of these cases, 121 (81%) were
generalized, 20 (13%) were localized, and nine (6%) were cephalic tetanus.
Previous Vaccination Status
Tetanus vaccination status was known for 89 (46%) of the 192 patients, and age
was known for 86 (97%) of these 89 patients. Of the nine patients aged <20 years for
whom vaccination status was reported, five had received no previous doses of a
TT-containing vaccine, three had received four doses, and one had received five
doses. Of the 77 patients aged ≥20 years for whom this information was reported,
42 (55%) had received no previous doses of TT, 17 (22%) had received a single dose,
and 18 (23%) had received at least three doses.
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*Per 100,000 population.
FIGURE 3. Reported number of tetanus cases, average annual incidence rates,* and
survival status of patients, by age group — United States, 1991–1994
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Twenty-three (12%) of the 192 patients were reported to have received at least a
primary series (i.e., three or more doses) of TT before onset of illness (Table 1). Of
these patients, 13 were reported to have received the last booster ≤10 years before
onset of illness. For two patients, this information was verified by records obtained
from their primary health-care providers. The first patient was a 12-year-old girl who
had onset of illness during 1994. She had previously received five doses of DTP, the
last of which was received 4 years before onset of illness. She was not hospitalized,
and she recovered without sequelae after 6 weeks of home care. The second patient
was a 29-year-old man who had a history of amphetamine abuse. He had previously
received four doses of a TT-containing vaccine, the last dose of which was received
6 years before onset of illness. He also recovered.
Two cases occurred in persons who did not receive vaccination because of
religious objections (i.e., a 12-year-old boy in Montgomery, Georgia, and a 17-year-old
boy in Lancaster, Pennsylvania). Both patients had generalized forms of tetanus and
required mechanical ventilation.
Type of Injury, Wound Treatment, and Prophylaxis
An acute injury sustained before onset of illness was identified for 148 (77%) of the
192 tetanus cases. Of these cases, 72 (49%) occurred after puncture wounds. The most
frequently reported type of puncture wound was sustained by stepping on a nail,
which was reported by 23 (16%) of all patients who had sustained an identified acute
injury. The other most frequently reported types of acute injury were lacerations (20%)
and abrasions (12%). Five patients had been bitten or scratched by animals, including
one patient who reported having been scratched in the face by a peacock.
The site of the antecedent acute injury was a lower extremity in 77 (52%) cases, an
upper extremity in 50 (34%) cases, and the head or trunk in eight (5%) cases. The
injury site was not specified for 13 cases.
The median incubation period was 7 days (range: 0–90 days) for the 138 patients
for whom the dates of both the antecedent injury and the onset of illness were speci-
fied. The incubation period was ≤45 days for all but one case, which occurred in a
64-year-old woman who was on long-term immunosuppressive therapy and whose
immunization status was unknown. This woman had been bitten on one of her legs by
a dog 90 days before onset of illness, and her wound ulcerated. She died after 75 days
of treatment. The incubation period for most (101 [73%]) of the 138 tetanus cases
ranged from 4 to 14 days; this period was ≤3 days for 21 (15%) cases and >14 days for
16 (12%) cases.
TABLE 1. Tetanus toxoid vaccination status of persons with reported tetanus — United
States, 1991–1994
Vaccination status No. (%)
0 doses  49 ( 25.5)
1 dose  17 (  8.9)
2 doses   0 (  0.0)
3 doses   5 (  2.6)
≥4 doses  18 (  9.4)
Unknown 103 ( 53.6)
Total 192 (100.0)
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The environment in which the antecedent injury occurred was reported for 117 pa-
tients. Of these patients, 57 (49%) were injured while indoors; 36 (31%), while per-
forming outdoor farming or gardening activities; and 23 (20%), while engaged in other
outdoor activities. One (1%) patient had sustained motor-vehicle–related injuries.
Information regarding medical care was reported for 135 patients who became ill
with tetanus after sustaining an acute wound; of these patients, 51 (38%) had obtained
medical care for the injury. TT was administered as prophylaxis to 22 patients (i.e.,
43% of those who obtained medical care), 15 (68%) of whom received toxoid within
4 days after the injury. In accordance with the recommendations of the Advisory Com-
mittee on Immunization Practices (ACIP) for the use of adult formulation Td and TIG in
wound management (Table 2) (32 ), 22 (92%) of the 24 patients who had obtained
medical care for an acute injury but were not administered Td should have received
the toxoid. Information regarding administration of toxoid was unavailable for the re-
maining five patients.
Thirteen patients who had acute wounds severe enough to have received prophy-
lactic wound debridement were candidates for both Td and TIG (Table 2); five of these
patients were administered Td in the course of wound management, and three were
administered TIG.
Twenty-three cases unrelated to acute injury were associated with either diabetes
(seven patients, five of whom were insulin-dependent) or chronic wounds (e.g., skin
ulcers, abscesses, or gangrene) (21 patients). Five patients were reported as having
both diabetes and a chronic wound. The only risk factor associated with tetanus for
one patient was a history of parenteral drug abuse.
Surgery performed 3–21 days before onset of illness was reported for seven
patients; for six of these patients, it was the only reported risk factor for tetanus
(the other patient had concomitant insulin-dependent diabetes mellitus). For these
cases, the median interval between surgery and onset of illness was 7 days (range:
2–13 days). None of these patients were known to have received TT during the
10 years preceding the surgery. One patient had surgery performed on the leg; three
TABLE 2. Summarized recommendations for the use of tetanus prophylaxis in rou-
tine wound management — Advisory Committee on Immunization Practices (ACIP),
1991 (7 )
  History of adsorbed
   tetanus toxoid
Clean, minor wounds All other wounds*
Td† TIG§ Td TIG
Unknown or <3 doses Yes No Yes Yes
≥3 doses¶   No** No   No†† No
 *Such as, but not limited to, wounds contaminated with dirt, feces, soil, or saliva; puncture
wounds; avulsions; and wounds resulting from missiles, crushing, burns, or frostbite.
†For children aged <7 years; the diphtheria and tetanus toxoids and pertussis vaccine
(DTP)—or pediatric diphtheria and tetanus toxoids (DT), if pertussis vaccine is
contraindicated—is preferred to tetanus toxoid (TT) alone. For persons aged ≥7 years, the
tetanus and diphtheria toxoids (Td) for adults is preferred to TT alone.
§TIG=tetanus immune globulin.
¶If only three doses of fluid toxoid have been received, a fourth dose of toxoid—preferably
an adsorbed toxoid—should be administered.
**Yes, if >10 years have elapsed since last dose.
††Yes, if >5 years have elapsed since last dose. (More frequent boosters are not needed and
can accentuate side effects.)
Vol. 46 / No. SS-2 MMWR 21
patients, the hips and sacral area; and three patients, the abdomen (i.e., by lap-
arotomy). The mean age of patients who had undergone surgery was 51 years (range:
21–77 years). One patient, an unimmunized 63-year-old woman who had had toe sur-
gery, died as a result of tetanus. Information regarding acute injury, chronic wound, or
other preexisting medical conditions was unavailable for 14 patients.
Clinical Features and Treatment
Information concerning therapeutic use of TIG was available for 168 patients; of
these patients, 163 (97%) reported having received TIG. The exact dosage of TIG was
specified for 115 (71%) of the 163 patients; the median dosage used therapeutically
was 3,000 IU (range: 250–10,000 IU). The time interval between onset of illness and
TIG administration was known for 146 of the patients who received TIG; TIG was
administered to 42 (29%) of these patients <24 hours after onset of illness and to
52 (36%) patients from 1 to 4 days after onset. Information concerning illness outcome
was reported for 157 patients who received TIG; 35 (22%) of these patients died. Two
(40%) of the five patients who did not receive TIG died. This difference was not statis-
tically significant (relative risk [RR]=0.56; 95% confidence interval [CI]=0.18<RR<1.7).
Initial (Wilcoxon rank sum test: p=0.67) or total (Wilcoxon rank sum test: p=0.46) dos-
age of TIG did not differ significantly between patients who died and those who
recovered.
The length of hospitalization was reported for 131 patients; the median duration
was 15 days (range: 0–92 days). Information regarding the use of assisted ventilation
was available for 151 patients; of these patients, 101 (67%) required ventilation. Infor-
mation concerning both the outcome and the use of assisted ventilation was available
for 145 patients; of these, 29 (30%) of the 98 patients who required ventilation died,
compared with two (4%) of the 47 who did not require ventilation.
The direct costs of medical care were assessed for the 10 cases reported by Texas
during 1991; the median cost was $65,651 (range: $12,099–$154,200) (J. Pelosi, Texas
Department of Health, personal communication). The cost of hospitalization, including
physicians’ fees, for the two tetanus cases reported by Kansas during 1993 was
$145,329 and $151,492 (15 ).
DISCUSSION
The epidemiology of reported tetanus in the United States during 1991–1994 was
similar to that during the 1980s (10–13 ). Tetanus continued to be a severe disease
primarily of older adults who were unvaccinated or inadequately vaccinated. Data ob-
tained from a national population-based serologic survey (16 ) indicate that the
prevalence of immunity to tetanus in the United States is lower in older age groups,
from >80% among persons aged 6–39 years to 28% among persons aged ≥70 years.
Previous serologic studies also have indicated that older adults lack protective levels
of tetanus antibodies (17–19 ) and that elderly persons who reside in rural areas are
more likely to be unimmunized than elderly persons in urban areas (20 ).
Tetanus is preventable through both vaccination and appropriate wound prophy-
laxis. Vaccination with a primary series of three doses of TT-containing vaccine and
booster doses of Td every 10 years is highly effective in preventing tetanus (21 ).
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During 1991–1994, only 26% of patients with known vaccination history had com-
pleted a primary series of TT before onset of tetanus, and in only two cases was vac-
cination against tetanus in the 10 years preceding onset of tetanus verified.
Tetanus remains a clinical diagnosis because confirmatory laboratory tests are not
available for routine use. Isolation of the organism from wounds is neither sensitive
nor specific, because a) anaerobic cultures of tissues or aspirates usually are not posi-
tive and b) the organism might be grown from wounds in the absence of clinical signs
and symptoms of disease (22–24 ). 
The number of tetanus cases derived from passive reporting by physicians to local
and state health departments underestimates the true incidence of tetanus in the
United States. Completeness of reporting for tetanus mortality has been estimated at
40%, while completeness of reporting for tetanus morbidity may be even lower (25 ).
Although tetanus reporting is incomplete, an analysis of tetanus mortality reporting
suggests that the reported tetanus cases are representative of all tetanus cases (25 ).
As noted previously (10–13 ), most (77%) tetanus cases occurred after an acute in-
jury was sustained; stepping on a nail was the most frequent cause of these injuries.
Acute-wound–associated tetanus can be prevented by appropriate wound manage-
ment, including active and/or passive immunization. Only 38% of patients for whom
this information was available had obtained medical care for the acute injury; accord-
ing to current ACIP recommendations (Table 2), 43% of these patients should have
received prophylaxis but did not. Approximately half the antecedent injuries occurred
indoors, emphasizing the need to consider such injuries as being risk factors for teta-
nus. The median incubation period between the antecedent injury and onset of
tetanus was 7 days; in all but one case, this time period was <45 days. More than 80%
of cases were diagnosed as generalized tetanus.
No cases of neonatal tetanus were reported during this 4-year period. Only one
case of neonatal tetanus, which occurred during 1989 in an infant born to an unvacci-
nated mother, was reported during 1984–1994 (10–13 ). Although almost all tetanus
cases in the United States occur in adults, most reported cases of tetanus worldwide
occur as neonatal tetanus (26–28 ). Neonatal tetanus can be prevented through mater-
nal vaccination and hygienic delivery practices, and the World Health Organization has
targeted neonatal tetanus for elimination (27,28 ).
When immunization programs are in place, the age distribution of patients usually
reflects the remaining susceptibility to the infection in the population (29 ). During
1991–1994, two tetanus cases occurred in persons aged 12 and 17 years who were
members of communities that object to vaccination. Persons who object to vaccina-
tion because of religious or philosophical beliefs may disproportionately contribute to
the remaining tetanus burden in the United States (30 ).
During 1991–1994, more than half the total number of reported cases occurred
in persons aged ≥60 years. In January 1994, the National Vaccine Advisory Committee
concluded that vaccine-preventable diseases among adults in the United States were
a continuing cause of morbidity and mortality, particularly among older persons (31 ).
Adult immunization levels may be markedly increased by reducing missed opportuni-
ties to vaccinate adults during health-care visits (32 ). During 1991–1994, recent
surgery was the only known injury for seven (4%) patients; TT had not been adminis-
tered preoperatively to these patients, although none had a history of vaccination
during the preceding 10 years. Because persons of all ages are exposed to tetanus,
Vol. 46 / No. SS-2 MMWR 23
maintaining protection against tetanus (and diphtheria) after the primary series can be
achieved by routinely scheduling booster doses of Td at decade ages (e.g., at 30, 40,
and 50 years of age) (7 ).
ACIP recommended recently that persons be routinely scheduled for a vaccination
visit at age 11–12 years and age 50 years (33 ). Such visits enable health-care provid-
ers to a) review the patient’s vaccination status, b) administer Td as indicated, and
c) determine whether a patient needs other vaccinations, such as influenza and pneu-
mococcal vaccinations (34,35 ). Full implementation of these recommendations and
compliance with the decennial Td booster policy should virtually eliminate the re-
maining tetanus burden in the United States.
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Abstract
Problem/Condition: Malaria is caused by infection with one of four species of Plasmo-
dium (P. falciparum, P. vivax, P. ovale, and P. malariae ), which are transmitted by
the bite of an infective female Anopheles sp. mosquito. Most malaria cases in the
United States occur among persons who have traveled to areas (i.e., other countries)
in which disease transmission is ongoing. However, cases are transmitted occasion-
ally through exposure to infected blood products, by congenital transmission, or by
local mosquito-borne transmission. Malaria surveillance is conducted to identify epi-
sodes of local transmission and to guide prevention recommendations.
Reporting Period Covered: Cases with onset of illness during 1993.
Description of System: Malaria cases confirmed by blood smear are reported to local
and/or state health departments by health-care providers and/or laboratories. Case
investigations are conducted by local and/or state health departments, and the reports
are transmitted to CDC.
Results: CDC received reports of 1,275 cases of malaria in persons in the United States
and its territories who had onset of symptoms during 1993; this number represented
a 40% increase over the 910 malaria cases reported for 1992. P. vivax, P. falciparum,
P. ovale, and P. malariae were identified in 52%, 36%, 4%, and 3% of cases, respec-
tively. The species was not determined in the remaining 5% of cases. The 278 malaria
cases in U.S. military personnel represented the largest number of such cases since
1972; 234 of these cases were diagnosed in persons returning from deployment in
Somalia during Operation Restore Hope. In New York City, the number of reported
cases increased from one in 1992 to 130 in 1993. The number of malaria cases ac-
quired in Africa by U.S. civilians increased by 45% from 1992; of these, 34% had been
acquired in Nigeria. The 45% increase primarily reflected cases reported by New York
City. Of U.S. civilians who acquired malaria during travel, 75% had not used a chemo-
prophylactic regimen recommended by CDC for the area in which they had traveled.
Eleven cases of malaria had been acquired in the United States: of these cases, five
were congenital; three were induced; and three were cryptic, including two cases that
were probably locally acquired mosquito-borne infections. Eight deaths were associ-
ated with malarial infection.
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Interpretation: The increase in the reported number of malaria cases was attributed to
a) the number of infections acquired during military deployment in Somalia and
b) complete reporting for the first time of cases from New York City.
Actions Taken: Investigations were conducted to collect detailed information concern-
ing the eight fatal cases and the 11 cases acquired in the United States. Malaria
prevention guidelines were updated and disseminated to health-care providers.
Persons who have a fever or influenza-like illness after returning from a malarious
area should seek medical care, regardless of whether they took antimalarial chemo-
prophylaxis during their stay. The medical evaluation should include a blood smear
examination for malaria. Malaria can be fatal if not diagnosed and treated rapidly.
Recommendations concerning prevention and treatment of malaria can be obtained
from CDC.
INTRODUCTION
Malaria is caused by infection with one of four species of Plasmodium (P. vivax,
P. falciparum, P. ovale, and P. malariae ). Infection is transmitted by the bite of an infec-
tive female Anopheles sp. mosquito. Forty percent of the world’s population live in
areas where malaria is transmitted (e.g., parts of Africa, Asia, Central America,
Hispaniola, North America, Oceania, and South America). In the past, malaria was
endemic throughout much of the continental United States. During the late 1940s, a
combination of improving socioeconomic conditions, water management, vector-
control efforts, and case management was successful at interrupting malaria
transmission in the United States (1 ). Since then, malaria case surveillance has
been maintained to detect locally acquired cases that could indicate reintroduction of
mosquito-borne transmission.
Through 1993, almost all cases of malaria diagnosed in the United States were im-
ported from regions of the world where malaria transmission was known to occur.
Each year, a few congenital infections and infections resulting from exposure to in-
fected blood and blood products have been acquired in the United States. In addition,
outbreaks of malaria that were probably acquired through local mosquito-borne trans-
mission were identified during 1989–1992 (i.e., California, outbreaks in 1988, 1989, and
1990; Florida, 1990; and New Jersey, 1991) (2–4 ).
State and/or local health departments and CDC thoroughly investigate all malaria
cases acquired in the United States, and CDC conducts an analysis of all imported
malaria cases to detect trends in acquisition. This information has been used to guide
recommendations for preventing malaria among persons who travel abroad. For ex-
ample, an increase in P. falciparum malaria among travelers returning from Africa, an
area with increasing incidence of chloroquine-resistance, prompted CDC in 1990 to
change the recommended chemoprophylaxis from chloroquine to mefloquine (5 ).
This report summarizes malaria cases reported to CDC for 1993.
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METHODS
Sources of Data
Malaria surveillance is a passive system; cases of blood-slide–confirmed malaria
are identified by health-care providers, infection-control practitioners, and/or labora-
tories. A slide-confirmed case is reported to local and/or state health departments, and
a standard form that contains clinical, laboratory, and epidemiologic information is
completed. This information is transmitted to the state health department and then to
CDC. CDC staff review all report forms at the time of receipt and request additional
information if necessary (e.g., if no recent travel is reported or chemoprophylaxis
failure is suspected). CDC directly obtains reports of other cases from health-care
providers who request assistance with the diagnosis and treatment of malaria. In ad-
dition, records of CDC’s National Malaria Reference Laboratory are reviewed, and case
report forms are completed for all patients who have smear-positive infection that
have not already been reported. All cases that have been acquired in the United States
are fully investigated, including all induced and congenital cases and possible
introduced or cryptic cases. Information derived from uniform case report forms con-
cerning all slide-confirmed cases is entered into a computer data base and analyzed
annually.
Definition of Terms
The following definitions are used in this report:
• Laboratory criteria for diagnosis: Demonstration of malaria parasites in blood
films.
• Confirmed case: Symptomatic or asymptomatic illness that occurs in the United
States in a person who has microscopically confirmed malaria parasitemia, re-
gardless of whether the person had previous attacks of malaria while in other
countries. A subsequent attack of malaria occurring in a person is counted as an
additional case if the demonstrated Plasmodium species differs from the initially
identified species. A subsequent attack of malaria occurring in a person while in
the United States could indicate a relapsing infection or treatment failure result-
ing from drug resistance if the demonstrated Plasmodium species is the same
species identified previously.*
This report also uses terminology derived from the recommendations of the World
Health Organization (WHO) (6 ). Definitions of the following terms are included for
reference.
• Autochthonous malaria:
– Indigenous. Malaria acquired by mosquito transmission in an area where
malaria occurs regularly. 
*To confirm the diagnosis of blood smears from questionable cases and to obtain appropriate
treatment recommendations, contact either your state or local health department or CDC’s
National Center for Infectious Diseases, Division of Parasitic Diseases, Malaria Epidemiology
Section; telephone (770) 488-7760.
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– Introduced. Malaria acquired by mosquito transmission from an imported
case in an area where malaria does not occur regularly.
• Imported malaria: Malaria acquired outside a specific area. In this report, im-
ported cases are those acquired outside the United States and its territories.
• Induced malaria: Malaria acquired through artificial means (e.g., blood transfu-
sion, common syringes, or malariotherapy).
• Relapsing malaria: Renewed manifestation (i.e., of clinical symptoms and/or
parasitemia) of malarial infection that is separated from previous manifestations
of the same infection by an interval greater than those caused by the usual peri-
odicity of the paroxysms.
• Cryptic malaria: An isolated malaria case that cannot be linked epidemiologically
to secondary cases.
Microscopic Diagnosis of Malaria
The early diagnosis of malaria requires that physicians consider malaria in the
differential diagnosis of every patient who has an unexplained fever; the evaluation of
such patients should include taking a comprehensive travel history. If malaria is sus-
pected, a Giemsa-stained smear of the patient’s peripheral blood should be examined
for parasites. Thick and thin blood smears must be prepared properly because the
accuracy of diagnosis depends on the quality of the blood film and the experience of




CDC received reports of 1,275 malaria cases that had onset of symptoms during
1993 among persons in the United States and its territories. This represented a 40%
increase over the 910 cases of malaria reported for 1992 and was the highest total
number of cases reported to CDC since 1980 (7 ). In 1993, 11 of the 1,275 cases had
been acquired in the United States.
Since 1973, malaria in civilians has accounted for most cases reported to CDC
(Table 1). During 1993, 519 (41%) reported cases of malaria were diagnosed in U.S.
civilians, representing a 31% increase from the 394 cases reported for 1992 (Figure 1).
The 453 (36%) malaria cases in foreign civilians constitutes a 6% decrease from the
481 cases reported for 1992. For each year from 1975 through 1992, malaria cases in
U.S. military personnel accounted for no more than 5% of reported cases. In 1993,
however, malaria in U.S. military personnel accounted for 278 (22%) reported cases,
representing an almost tenfold increase over the 29 cases reported for 1992.
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Plasmodium  Species
The Plasmodium species was identified in 1,216 (95%) of the 1,275 cases reported
for 1993. P. vivax was identified from blood smears in 663 (52%) cases, representing a
43% increase from the 463 cases for 1992 (Table 2). The 457 (36%) P. falciparum cases
identified during 1993 represented a 54% increase from the 296 cases reported for
1992. P. malariae and P. ovale were identified in 53 (4%) and 41 (3%) of cases, respec-
tively. Two mixed infections were reported. The species was undetermined in 59 (5%)
cases.
TABLE 1. Number of malaria cases* in U.S. and foreign civilians and U.S. military








1966   621  89  32 22   764
1967 2,699  92  51 15 2,857
1968 2,567  82  49 0 2,698
1969 3,914  90  47 11 4,062
1970 4,096  90  44 17 4,247
1971 2,975  79  69 57 3,180
1972   454 106  54 0   614
1973    41 103  78 0   222
1974    21 158 144 0   323
1975    17 199 232 0   448
1976     5 178 227 5   415
1977    11 233 237 0   481
1978    31 270 315 0   616
1979    11 229 634 3   877
1980    26 303 1,534  1 1,864
1981    21 273 809 0 1,103
1982     8 348 574 0   930
1983    10 325 468 0   803
1984    24 360 632 0 1,016
1985    31 446 568 0 1,045
1986    35 410 646 0 1,091
1987    23 421 488 0   932
1988    33 550 440 0 1,023
1989    35 591 476 0 1,102
1990    36 558 504 0 1,098
1991    22 585 439 0 1,046
1992    29 394 481 6   910
1993   278 519 453 25 1,275
*A case was defined as symptomatic or asymptomatic illness that occurs in the United States
in a person who has microscopically confirmed malaria parasitemia, regardless of whether
the person had previous attacks of malaria while in other countries. A subsequent attack of
malaria occurring in a person is counted as an additional case if the demonstrated Plasmodium
species differs from the initially identified species. A subsequent attack of malaria occurring
in a person while in the United States could indicate a relapsing infection or treatment failure
resulting from drug resistance if the demonstrated Plasmodium  species is the same species
identified previously.
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Area of Acquisition and of Diagnosis
The number of malaria infections acquired in Africa during 1993 (745 [58%] cases)
was more than twice the number of cases acquired there during 1992 (337 [37%]
cases) (Table 3). Of cases reported for 1993, 259 (20%) cases had been acquired in
Asia, representing a 22% decrease from the 330 (36%) cases for 1992.
In the United States, cases are reported by the state in which they are diagnosed
(Figure 2). The number of cases reported from New York State (excluding New York















*Includes Puerto Rico, the Virgin Islands, and Guam.
†The large increase in the number of cases reported for 1980 primarily reflected cases diag-
nosed in immigrants from Southeast Asia after the Vietnam conflict.
FIGURE 1. Number of malaria cases in U.S. and foreign civilians — United States,*
1967–1993†
TABLE 2. Number of malaria cases, by Plasmodium  species — United States, 1992 and
1993
 Plasmodium 
   species
1992 1993
No. (%) No. (%)
P. vivax 463 ( 50.9) 663 ( 52.0)
P. falciparum 296 ( 32.5) 457 ( 35.8)
P. malariae  39 (  4.3)  53 (  4.2)
P. ovale  28 (  3.1)  41 (  3.2)
Undetermined  84 (  9.2)  59 (  4.6)
Mixed   0 (  0.0)   2 (  0.2)
Total 910 (100.0) 1,275 (100.0)
32 MMWR February 21, 1997
City) increased from 77 in 1992 to 191 in 1993; this increase primarily reflected the
107 cases diagnosed in military personnel returning from Somalia. The number of
cases in North Carolina decreased from 85 in 1992 to 42 in 1993; this decrease primar-
ily reflected a decrease in the number of cases in Montagnard refugees arriving in the
state. In addition, New York City began submitting case reports to CDC in 1993. One
hundred thirty cases were reported from New York City for 1993, compared with one
case for 1992.
Interval Between Arrival and Onset of Illness
Of those persons who became ill with malaria after arriving in the United States,
the interval between the dates of arrival and the onset of illness was known for
847 persons. The species was not identified for 37 of the 847 cases, and one case was
a mixed infection. Of the remaining 809 cases caused by a single infecting Plasmo-
dium species, symptoms developed within 30 days after the person’s arrival in
the United States in 278 (88%) of 316 P. falciparum infections and in 84 (20%) of
431 P. vivax infections (Table 4). Nineteen (2%) of these 809 infected persons became
ill >1 year after arrival in the United States. Another 58 persons reportedly became ill
from 1 to 163 days before arrival in the United States. Thirty-six (62%) of these 58 per-

















































*Of the 1,275 malaria cases reported for 1993, only 11 cases had been acquired in the United
States. Five of these cases had been acquired congenitally, and three had been acquired
through transfusion of blood or blood products. Two cases probably were locally acquired,
and one case probably resulted from a needlestick injury.
FIGURE 2. Number of malaria cases, by state in which the disease was diagnosed*
— United States, 1993
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TABLE 3. Number of malaria cases, by Plasmodium  species and area of acquisition —
United States, 1993 — Continued
Area of acquisition
Plasmodium  species
TotalP. vivax P. falciparum P. malariae P. ovale Mixed Unknown
AFRICA 256 376 39 36 0 38 745
Algeria   0   0 0  0 0  0   0
Angola   0   1 0  0 0  0   1
Benin   0   0 0  1 0  0   1
Burkina Faso   0   1 0  0 0  0   1
Cameroon   0  11 0  4 0  1  16
Central African Republic   0   2 1  0 0  0   3
Chad   0   1 0  0 0  0   1
Congo   0   1 0  0 0  0   1
Djibouti   0   0 0  0 0  0   0
Egypt   0   0 0  0 0  0   0
Equatorial Guinea   0   0 0  0 0  0   0
Ethiopia   5   2 0  0 0  0   7
Gambia   0   0 1  0 0  0   1
Ghana   1  36 0  3 0  6  46
Guinea   1   0 0  0 0  0   1
Guinea-Bissau   0   1 1  0 0  0   2
Ivory Coast   1  21 1  0 0  0  23
Kenya   6  20 5  3 0  0  34
Liberia   2  12 1  2 0  0  17
Madagascar   2   1 0  0 0  0   3
Malawi   0   1 0  2 0  1   4
Mali   0   7 0  0 0  0   7
Mauritania   0   0 0  0 0  0   0
Mozambique   0   0 0  1 0  0   1
Niger   0   0 0  0 0  1   1
Nigeria   3 135 11  8 0 11 168
Rwanda   0   1 0  0 0  0   1
Senegal   0  10 0  0 0  0  10
Sierra Leone   0  22 3  2 0  2  29
Somalia 216  12 2  1 0  7 238
South Africa   0   0 0  0 0  0   0
Sudan   5  12 1  0 0  1  19
Tanzania   0   4 0  0 0  0   4
Togo   0   3 0  0 0  1   4
Uganda   3   8 0  4 0  1  16
Zaire   0   1 2  0 0  0   3
Zambia   1   2 0  0 0  0   3
Zimbabwe   0   1 0  0 0  1   2
Africa, Central*   1   0 0  1 0  0   2
Africa, East*   5  14 2  1 0  1  23
Africa, South*   1   5 0  0 0  0   6
Africa, West*   1  17 3  1 0  1  23
Africa, Unspecified*   2  11 5  2 0  3  23
ASIA 214  28 2  2 0 13 259
Afghanistan   0   0 0  0 0  0   0
Bangladesh   3   0 0  0 0  0   3
Cambodia   0   0 0  0 0  1   1
China   0   0 0  0 0  0   0
India 154  16 0  1 0  9 180
Indonesia  11   1 0  0 0  2  14
Laos   1   2 0  0 0  1   4
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TABLE 3. Number of malaria cases, by Plasmodium  species and area of acquisition —
United States, 1993 — Continued
Area of acquisition
Plasmodium  species
TotalP. vivax P. falciparum P. malariae P. ovale Mixed Unknown
ASIA (cont’d)
Malaysia   0 0 0 0 0 0    0
Myanmar (Burma)   1 0 0 0 0 0    1
Nepal   1 0 0 0 0 0    1
Pakistan  15 2 0 0 0 0   17
Philippines   3 0 0 0 0 0    3
Saudi Arabia   1 0 0 0 0 0    1
Sri Lanka   1 0 0 0 0 0    1
Thailand   3 1 1 0 0 0    5
Vietnam  10 1 1 1 0 0   13
Yemen   0 1 0 0 0 0    1
Asia, Southeast*   3 2 0 0 0 0    5
Asia, Unspecified*   7 1 0 0 0 0    8
Middle East, Unspecified*   0 1 0 0 0 0    1
CENTRAL AMERICA
AND CARIBBEAN 106 30 5 1 2 2  146
Belize   7 0 0 0 0 1    8
Caribbean, Unspecified*   0 0 1 0 0 0    1
Costa Rica   2 0 0 0 0 0    2
Dominican Republic   2 0 0 0 0 0    2
El Salvador   9 0 0 0 0 0    9
Guatemala  19 3 2 1 1 0   26
Haiti   0 20 0 0 0 0   20
Honduras  40 3 0 0 0 1   44
Nicaragua  10 1 0 0 1 0   13
Panama   0 0 1 0 0 0    0
Central America,
Unspecified*  17 3 1 0 0 0   21
NORTH AMERICA  16 5 1 0 0 1   23
Mexico  10 1 1 0 0 1   13
United States   6 4 0 0 0 0   10
SOUTH AMERICA  14 4 1 0 0 0   19
Brazil   2 0 0 0 0 0    2
Colombia   1 0 0 0 0 0    1
Ecuador   2 0 0 0 0 0    2
French Guiana   0 0 0 0 0 0    0
Guyana   1 3 1 0 0 0    5
Venezuela   6 1 0 0 0 0    7
South America,
Unspecified*   2 0 0 0 0 0    2
OCEANIA  35 1 1 2 0 3    42
Papua New Guinea  30 1 1 2 0 2   36
Solomon Islands   3 0 0 0 0 1    4
Vanuatu   0 0 0 0 0 0    0
Oceania, Unspecified*   2 0 0 0 0 0    2
Unknown  22 13 4 0 0 2   41
Total 663 457  53 41 2 59 1,275 
*Country unspecified.
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Imported Malaria Cases
Imported Malaria in Military Personnel
For 1993, 278 reported cases of imported malaria occurred in U.S. military person-
nel. Of these cases, 161 (58%) occurred in personnel of the U.S. Army; 100 (36%), the
U.S. Marine Corps; and nine (3%), the U.S. Air Force. Eight (3%) cases occurred in
military personnel for whom the service branch was not identified.
Of the total 278 cases, 234 (84%) were acquired in Somalia during Operation Re-
store Hope (8 ). P. vivax was the infecting species in 215 (92%) of these 234 cases, all
of which were considered relapse infections; P. falciparum was the infecting species in
10 (4%) cases. Of the remaining 44 (16%) cases reported in U.S. military personnel,
20 had been acquired in Honduras.
Imported Malaria In Civilians
Of the 961 imported malaria cases in civilians, 508 (53%) were diagnosed in U.S.
residents and 453 (47%) were in residents of other countries (Table 5). Of the 508 im-
ported malaria cases in U.S. civilians, 276 (54%) occurred in persons who had traveled
in Africa, representing a 45% increase over the 190 cases acquired in this region dur-
ing 1992. Ninety-five (34%) of the 276 U.S. civilians who acquired malaria in Africa
TABLE 5. Number of imported malaria cases in U.S. and foreign civilians, by area of
acquisition — United States, 1993
   Area of
acquisition
U.S. civilians Foreign civilians Total
No. (%) No. (%) No. (%)
Africa 276 ( 54.3) 213 ( 47.0) 489 ( 50.9)
Asia  91 ( 17.9) 157 ( 34.7) 248 ( 25.8)
Caribbean  11 (  2.2)  12 (  2.6)  23 (  2.4)
Central America  54 ( 10.6)  46 ( 10.2) 100 ( 10.4)
Mexico   5 (  1.0)   7 (  1.5)  12 (  1.2)
Oceania  38 (  7.5)   2 (  0.4)  40 (  4.2)
South America  17 (  3.3)   2 (  0.4)  19 (  2.0)
Unknown  16 (  3.1)  14 (  3.1)  30 (  3.1)
Total 508 (100.0) 453 (100.0) 961 (100.0)
TABLE 4. Number of imported malaria cases, by Plasmodium  species and by interval




TotalP. vivax P. falciparum P. malariae P. ovale
No. (%) No. (%) No. (%) No. (%) No. (%)
  0– 29  84 ( 19.5) 278 ( 88.0) 17 ( 51.5)  9 ( 31.0) 388 ( 48.0)
 30– 89 127 ( 29.5)  32 ( 10.1)  8 ( 24.2)  5 ( 17.2) 172 ( 21.3)
 90–179 107 ( 24.8)   1 (  0.3)  5 ( 15.2)  8 ( 27.6) 121 ( 15.0)
180–364  98 ( 22.7)   3 (  0.9)  2 (  6.1)  6 ( 20.7) 109 ( 13.5)
   ≥365  15 (  3.5)   2 (  0.6)  1 (  3.0)  1 (  3.4)  19 (  2.3)
Total 431 (100.0) 316 (100.0) 33 (100.0) 29 (100.0) 809 (100.0)
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reported having traveled in Nigeria, and 100 (36%) had traveled in other parts of West
Africa. Of the 453 cases of imported malaria in foreign civilians during 1993, 213 (47%)
had been acquired in Africa; in comparison, 142 cases had been acquired in Africa
during 1992. The 157 (35%) cases of imported malaria acquired during 1993 in Asia
by foreign civilians represented a 33% decrease from the 233 cases acquired in Asia
during 1992.
Use of Antimalarial Chemoprophylaxis
Information concerning use of chemoprophylaxis was available for 482 (95%) of
the 508 U.S. civilians who had imported malaria. Of these 482 persons, 229 (48%) had
not taken chemoprophylaxis, 116 (24%) had not taken a drug recommended by CDC
for the area visited, and 28 (6%) did not specify the type of chemoprophylaxis taken
(9 ). The remaining 109 (23%) persons reported having taken a medication recom-
mended by CDC for the area visited; however, 23 (21%) of these persons had not taken
the recommended dosage, and information was incomplete for 18 (17%). Fifty-seven
(52%) of these 109 cases were clinically consistent with relapses of P. vivax or P. ovale
infection.
The remaining 11 cases occurred in persons who reported having been compliant
with a regimen of mefloquine. Of these 11 cases, five were diagnosed as P. falciparum
infection, three cases of which had been acquired in West Africa. Serum levels of
mefloquine were measured on four of the five persons infected with P. falciparum, and
none had mefloquine levels adequate to provide protection from blood-stage infec-
tion (10 ). Illnesses in the remaining six persons who had been compliant with a
regimen of mefloquine were diagnosed as P. malariae infection 1–2 months after com-
pletion of chemoprophylaxis.
The purpose of travel to foreign countries with known malaria transmission was
reported for 303 (60%) of the 508 U.S. civilians who had imported malaria (Table 6). Of
these 303 persons, 63 (21%) had traveled to visit friends and relatives, 61 (20%) had
been tourists, and 56 (18%) had been conducting missionary work.
TABLE 6. Number of imported malaria cases in U.S. civilians, by purpose of travel at
the time of acquisition — United States, 1993
Category
Imported cases      
No. (%)
Business representative  41 (  8.1)
Government employee   6 (  1.2)
Missionary  56 ( 11.0)
Peace Corps volunteer   9 (  1.8)
Teacher/Student  48 (  9.4)
Tourist  61 ( 12.0)
Visiting a friend or relative  63 ( 12.4)
Other  19 (  3.7)
Unknown 205 ( 40.4)
Total 508 (100.0)
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Malaria Acquired in the United States
Congenital Malaria
The following five cases of congenital malaria were reported for 1993.
Case 1. On January 6, 1993, a 3-week-old girl was admitted to a hospital in Califor-
nia because of fever. An examination of the infant’s peripheral blood smear dem-
onstrated the presence of P. vivax parasites. She was successfully treated with chloro-
quine. The infant also received primaquine, although congenital infection does not
result in liver stage infection and, therefore, does not require such treatment for radi-
cal cure.
The infant’s mother, a resident of Tijuana, Mexico, had traveled in Guatemala
from December 1991 through January 1992. She had treated herself with an unknown
medication for malaria while in Guatemala. On December 21, 1992, while visit-
ing in California, she was admitted to a hospital, where she was diagnosed as having
P. vivax malaria and treatment with chloroquine was initiated. The infant was born on
December 22. After the delivery, the mother was treated with primaquine.
Case 2. In June 1993, an 18-day-old boy was admitted to a hospital in California
because of fever, anemia, and thrombocytopenia. An examination of the infant’s blood
smears demonstrated the presence of P. vivax. The symptoms and parasitemia re-
solved after treatment with chloroquine.
The infant’s mother had arrived recently from Guatemala, where she had been
treated for malaria during the first and seventh months of this pregnancy but had not
received chemoprophylaxis for prevention of relapses during the remainder of the
pregnancy. Blood smears obtained from the mother after diagnosis of the infant’s
infection reportedly demonstrated a dual infection with P. vivax and P. malariae;
however, the slides were not provided to CDC for confirmation. The mother was
treated with chloroquine, but her medical records did not indicate whether she also
was treated with primaquine.
Case 3. On July 12, 1993, a 7-week-old girl was admitted to a hospital in Florida
because of fever, irritability, splenomegaly, anemia, and thrombocytopenia. P. falci-
parum infection was diagnosed after examination of the infant’s blood smear, and she
was treated with quinine and pyrimethamine-sulfadoxine. Medical information
concerning the infant’s mother, who had resided recently in Sierra Leone, was not
available.
Case 4. During September 1993, a 3-week-old girl was admitted to a hospital in
California because of fever. Parasites consistent with P. vivax were present on exami-
nation of thick and thin blood smears. The infant was treated with chloroquine and
subsequently had resolution of fever and clearance of parasitemia.
Symptoms of malaria did not develop in the infant’s twin. The infants’ mother had
traveled from India 11 months before the delivery, and she reported having had febrile
episodes during the pregnancy. Indirect immunofluorescent antibody (IFA) assays
were performed on serum samples obtained from the mother and both twins. IgG and
IgM titers to P. vivax  for the parasitemic infant were 1:4,096 and 1:1,024, respectively.
Both the mother and the asymptomatic twin had high titers of serum IgG (1:1,024) but
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low titers of IgM (1:16 in the mother and <1:16 in the asymptomatic twin) to P. vivax.
The mother was treated with chloroquine and primaquine, and the asymptomatic twin
was not treated.
Case 5. During November 1993, a 7-week-old girl was admitted to a hospital in
Texas because of fever. An examination of her blood smear demonstrated the pres-
ence of parasites consistent with P. vivax. The child was treated with chloroquine, and
the symptoms and parasitemia resolved.
The child had been delivered by cesarean section because of abruptio placentae.
The mother had emigrated from India in January 1993 and had been treated for an
unspecified type of malaria at 4 months’ gestation; she reported no recurrent fevers
during her pregnancy. The mother’s blood smears were negative for parasites. Treat-
ment information on the mother was unavailable.
Cryptic Malaria
The following three cases of cryptic malaria were reported for 1993.
Cases 1 and 2. The first case occurred in a 27-year-old man who was admitted on
both July 20 and August 5, 1993, to a hospital in New York City; both hospitalizations
were for fever of unknown origin. On August 17, an examination of smears of a bone
marrow aspirate demonstrated the presence of parasites consistent with P. falci-
parum.
The second case occurred in a 22-year-old woman who was admitted to another
hospital in New York City on July 21, 1993, because of fever of unknown origin. On
August 4, her illness was diagnosed as malaria after an examination of her peripheral
blood smear demonstrated the presence of P. falciparum parasites.
The man had emigrated from Poland in May 1993 but reported never having trav-
eled to a country with known malaria transmission. The woman had never traveled
outside the United States. Neither person had ever received a blood transfusion, used
injection drugs, or sustained a needlestick injury. These two persons resided within
2 miles of each other.
The New York City Department of Health and CDC (11 ) investigated both cases and
determined that the two patients probably acquired malaria in New York City through
mosquito-borne transmission. In addition, a 17-year-old woman who lived within
2 miles of the first two patients was diagnosed on August 4 as having P. falciparum
malaria. This case was investigated as a possible case of local mosquito-borne infec-
tion; however, the infection was classified as imported malaria because the woman
had traveled to Thailand during July 1991.
Case 3. On March 29, 1993, fever developed in a 34-year-old woman 2 weeks after
she sustained a needlestick injury in the medical office where she was employed. The
woman did not seek medical care until April 5, when an examination of her blood
smears demonstrated the presence of P. falciparum parasites (8% of her red blood
cells were infected). She was treated initially with 1.25 g of mefloquine, 600 mg of
quinine, and 900 mg of clindamycin, followed by 250 mg of mefloquine daily for
the next 3 days. On April 8, she complained of right upper quadrant pain of unclear
etiology, and treatment for malaria was resumed with oral quinine sulfate. She died
the next day.
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The needlestick injury involved a syringe that had been used to obtain blood from
a patient who had arrived recently from Africa; blood smears obtained from this
patient were reportedly negative for parasites but were unavailable for review by CDC.
The woman had traveled several months before to Tijuana and Acapulco, Mexico,
which are not considered to be areas with known malaria transmission. She also had
traveled in Africa 5 years earlier. Because malarial symptoms developed in the woman
within 2 weeks after she sustained the needlestick injury and because she had not
traveled recently to an area in which malaria is endemic, the infection could have
resulted from the injury; however, a definitive conclusion regarding the source of in-
fection could not determined.
Induced Malaria
Case 1. In January 1993, illness in a 78-year-old man who had large cell lymphoma
was diagnosed at a Connecticut hospital as P. vivax infection. He had never traveled
outside the United States, but he had received multiple transfusions of blood and
blood products from 63 different donors. On the basis of the results of a survey ques-
tionnaire mailed to 59 of these donors, the 29 donors who had ever traveled to an area
in which malaria is endemic were tested serologically.
One platelet donor had a serum IFA assay titer of 1:256 to P. falciparum, 1:64 to
P. vivax, 1:64 to P. ovale, and <1:16 to P. malariae on blood obtained on August 31,
1993. An examination of this donor’s blood smears demonstrated the presence of
P. falciparum parasites. This donor had been born in India, and the last time he had
visited there before the platelet donation was in 1987. He again visited India from May
through July 1993 (i.e., between the time of the donation and the investigation of this
case). Repeat serologic testing on October 14 demonstrated an IFA assay titer of 1:64
for P. falciparum and 1:16,384 for P. vivax, the latter of which was consistent with
recent P. vivax infection. An examination of blood smears at that time did not demon-
strate the presence of parasites. The donor was treated for both P. vivax and
P. falciparum infection. Whether this donor was the source of the recipient’s infection
is uncertain, because the donor might have acquired malaria during his most recent
trip to India.
Case 2. On December 21, 1992, a 62-year-old man who had multiple myeloma was
admitted to a hospital in New York City because of fever. He was treated initially for
presumptive bacterial sepsis, but he continued to have febrile episodes. On January 7,
1993, a bone marrow aspirate was performed, and malaria parasites were identified
on microscopic examination. Subsequent examination of his peripheral blood smear
confirmed the diagnosis of P. falciparum infection, with a 12% level of parasitemia. He
was treated with intravenous quinidine and tetracycline with subsequent resolution of
fever and parasitemia.
The patient had been born in Russia and had moved to the United States 10 years
before the diagnosis of malaria. Two years before the diagnosis, he had vacationed in
Cancun, Mexico, although this is not an area with known malaria transmission. He had
received two units of packed red blood cells on November 22, 1992, and one unit of
packed red blood cells 7 days later. All three of the blood donors were subsequently
tested for malaria antibodies; a serum sample from one of these donors had a positive
reaction, with an IFA assay titer of >1:16,384 for P. falciparum malaria. The implicated
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donor was a man who had been born in Nigeria and who had been to both Nigeria and
Haiti during September 1992; however, he had not reported this information to the
blood bank at the time of the donation. An examination of blood smears obtained
from the donor demonstrated parasites consistent with P. falciparum. He was treated
with quinine sulfate and pyrimethamine-sulfadoxine.
Case 3. In December 1993, a 60-year-old woman who had received a liver transplant
the previous month was diagnosed as having P. vivax infection. She was treated suc-
cessfully with chloroquine and primaquine. She had been born in the United States
and had never traveled to an area in which malaria is endemic. She had received
110 units of blood and blood products during her hospitalization for the liver trans-
plantation. Serum was obtained from the liver donor and all donors from whom she
had received red blood cells and platelets. Only one platelet donor had detectable
antibodies for Plasmodium.
The implicated donor was a woman who had emigrated from Ghana in 1990; she
had not traveled out of the United States since her arrival. She was asymptomatic at
the time of donation. IFA assay titers of her serum were 1:1,024 for P. ovale, 1:1,024 for
P. malariae, 1:4,096 for P. falciparum, and 1:256 for P. vivax, a pattern consistent with
that of a person from a geographic area in which the incidence of malaria transmis-
sion is high. An examination of blood smears obtained from this donor demonstrated
rare ring forms consistent with Plasmodium infection, but a definitive species identifi-
cation was not possible.
Another person had received red blood cells from this donor. An IFA assay of this
recipient’s serum only identified antibodies to P. ovale (titer 1:64), and an examination
of this recipient’s blood smear did not demonstrate the presence of parasites. This
recipient was treated with chloroquine, and the donor was treated with chloroquine
and primaquine. A DNA amplification using polymerase chain reaction of blood sam-
ples obtained from the donor and the first recipient (i.e., the person with the initially
diagnosed infection) identified the infecting species as P. ovale, thus highlighting the
limitations of using parasite morphology for species identification—particularly when
differentiating P. vivax and P. ovale.
Deaths Attributed to Malaria
The following eight deaths were attributed to malaria during 1993.
Case 1. A 32-year-old woman in her 35th week of pregnancy came to the United
States from Liberia on March 13, 1993. She had had an illness that was diagnosed as
malaria in June 1992, for which she was treated with chloroquine and pyrimethamine.
Her pregnancy was complicated by preeclampsia. Two days after arrival in the United
States, she became ill with myalgia and fever (103 F). She was hospitalized on
March 20. An examination of her blood smear demonstrated the presence of parasites
consistent with P. falciparum, and treatment with oral quinine sulfate was initiated. On
March 21, adult respiratory distress syndrome and hypoglycemia developed in the
woman. Two days later, pyrimethamine-sulfadoxine was included in her treatment
regimen. Because her respiratory status was deteriorating rapidly, a cesarean section
was performed on March 23. The woman’s respiratory status continued to worsen,
and she died on March 30.
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The woman’s infant girl weighed 2.5 kg and was apparently healthy. Although
an examination of placental sections demonstrated the presence of P. falciparum
parasites, no parasites were demonstrated on blood smears obtained from the infant
on March 24.
Case 2. On April 17, 1993, a 51-year-old woman returned from traveling in South
Africa and Zimbabwe. She had taken chloroquine for antimalarial chemoprophylaxis
while traveling. Fever developed in the woman on April 24, and an examination of the
woman’s blood smear on April 26 demonstrated the presence of P. falciparum para-
sites. She was treated with a single dose of 1.5 g of mefloquine on April 27. She
continued to have febrile episodes; on April 30, she complained of intense left ear pain
and was leukopenic (white blood cell count of 2000/mm
3
). Doxycycline and nor-
floxacin were added to her treatment regimen for additional coverage against P. falci-
parum and bacterial pathogens. The patient had a cardiac arrest and died on April 31.
Case 3. A 24-year-old male U.S. resident was working as a volunteer in the jungles
of Guyana. He had not been taking antimalarial chemoprophylaxis. On March 29,
1993, he was hospitalized in Guyana because of fever. Detailed information concern-
ing this hospitalization was unavailable. He was airlifted to a hospital in Miami on
April 5, at which time he had altered mental status. He died within an hour after his
arrival. A postmortem examination indicated cerebral malaria caused by P. falciparum
infection.
Case 4. On November 11, 1993, a 51-year-old woman returned from a 2-week visit
to Nigeria, where she had taken hydroxychloroquine as antimalarial chemoprophy-
laxis. Fever developed in the woman on November 17, and she was hospitalized the
next day. A blood smear obtained from the woman was examined and reported to be
negative for parasites. On November 21, she became lethargic and had lactic acidosis.
She was transferred to another hospital on November 22, at which time she had al-
tered mental status consistent with cerebral malaria. An examination of her blood
smear demonstrated the presence of P. falciparum parasites (4% of her red blood cells
were infected). Treatment with intravenous quinidine and oral pyrimethamine-
sulfadoxine was initiated at the time of admission. During her hospitalization, she was
diagnosed with adult respiratory distress syndrome and required mechanical ventila-
tion. She subsequently acquired nosocomial bacterial pneumonia. She died as a result
of respiratory failure on December 15.
Case 5. In June 1993, a 63-year-old female native of India traveled to the United
States. She had had multiple episodes of malaria that had been treated in India.
On August 8, she was admitted to a hospital in Missouri because of fever (100.5 F),
nausea, vomiting, and diarrhea. An examination of her blood smears reportedly dem-
onstrated a mixed Plasmodium infection, and she was treated with oral quinine
sulfate and doxycycline. The symptoms of her illness improved markedly, and she
was discharged 2 days after admission. On August 14, after she had completed a
3-day course of quinine and was on her fourth day of treatment with doxycycline, she
was admitted to another hospital because of shortness of breath that required me-
chanical ventilation. A radiograph of her chest was consistent with pulmonary edema,
and an echocardiogram demonstrated diffuse cardiac dysfunction consistent with
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myocarditis or ischemia. Her cardiac enzymes were normal, excluding the diagnosis
of acute myocardial infarction. The patient died as a result of congestive heart failure.
Subsequent reexamination by CDC of the initial blood smears from the first hospitali-
zation demonstrated the presence of only P. vivax parasites (1.3% of her red blood
cells were infected). The underlying cause of myocardial disease was not determined.
Case 6. On January 10, 1993, a 67-year-old woman was admitted to a hospital in
Florida because of febrile episodes. An examination of her blood smears demon-
strated the presence of P. falciparum parasites. She was treated with quinine sulfate.
During her hospitalization, she was diagnosed with adult respiratory distress syn-
drome and cardiac arrhythmia, the latter of which caused her death on January 20.
The arrhythmia may have resulted from either P. falciparum-associated myocardial
dysfunction or an adverse reaction to quinine.
Case 7. On January 1, 1993, fever developed in a 30-year-old man 1 day after he
returned from a trip to Nigeria. He had not taken antimalarial chemoprophylaxis while
traveling. He was hospitalized on January 20 because of headache, nausea, and
vomiting. His illness was diagnosed initially as viral meningitis, but a subsequent ex-
amination of his blood smears identified P. falciparum parasitemia. Treatment with
quinine and pyrimethamine-sulfadoxine was initiated. He also was diagnosed as hav-
ing bacterial pneumonia, which was treated with a cephalosporin antibiotic, and mild
renal insufficiency. His temperature decreased with treatment. On January 24, the
patient signed out of the hospital against medical advice without completing his
prescribed course of quinine. On February 1, he was admitted to another hospital be-
cause of respiratory distress. An examination of his blood smears again demonstrated
the presence of P. falciparum parasites, and findings on his chest radiograph were
consistent with adult respiratory distress syndrome. He was treated with intravenous
quinidine, pyrimethamine-sulfadoxine, and clindamycin. His respiratory status did not
improve, and he died on February 6.
Case 8. See Cryptic Case #3.
DISCUSSION
The 1,275 cases of malaria reported to CDC for 1993 represented a 40% increase
from the 910 cases reported for 1992 (7 ). This increase was attributed primarily to two
events. First, the number of cases in military personnel increased almost tenfold, re-
flecting the 234 cases of malaria acquired in Somalia during Operation Restore Hope
(which occurred from December 1992 through May 1993) (8 ). This increase repre-
sented the largest number of malaria cases in military personnel in 1 year since the
peak in cases associated with the return of troops from Vietnam. Second, during 1993,
the New York City Department of Health began routinely sending all malaria case re-
port forms to CDC, reporting 130 cases for that year.
In comparison with 1992, the number of P. falciparum infections reported for 1993
in U.S. civilians returning from Africa increased by 45%; this overall increase primarily
reflected the increased number of cases acquired in Nigeria and other parts of West
Africa. Almost all these cases occurred in persons who had not taken a chemoprophy-
lactic regimen recommended by CDC.
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Failure to take the appropriate antimalarial chemoprophylaxis and noncompliance
with dosing regimens contributed to most of the imported malaria cases in U.S. civil-
ians during 1993. Only 25% of U.S. civilians diagnosed with malaria had taken an
appropriate chemoprophylactic medication recommended by CDC for their area of
travel. The drug recommended by CDC for travelers to areas with known transmission
of chloroquine-resistant P. falciparum is mefloquine (9 ). Excluding cases of relapse
infection and cases for which information was incomplete, symptomatic parasitemia
developed in only 11 patients who had correctly taken mefloquine for chemoprophy-
laxis. Serum mefloquine levels were found to be below a protective level for all four of
the five patients with P. falciparum infection who were tested. This may indicate non-
compliance or differences in metabolism of mefloquine in these persons (10 ). The
remaining six patients had P. malariae parasitemia >2 months after completion of their
chemoprophylactic regimen.
Health-care providers should contact CDC if chemoprophylaxis failure is suspected,
thus enabling measurement of serum levels of the chemoprophylactic agent. The de-
velopment of malarial infection in the setting of protective levels of mefloquine might
indicate the emergence of mefloquine-resistant strains of the parasite. Reported cases
of chloroquine-resistant P. falciparum infections in travelers returning from Africa
prompted CDC to revise the recommended antimalarial chemoprophylaxis for travel-
ers to that region (5 ).
The signs and symptoms of malarial illness are variable, but most patients experi-
ence fever. Other symptoms include headache, back pain, chills, increased sweating,
myalgia, nausea, vomiting, diarrhea, and cough. The diagnosis of malaria should be
considered for any person who has these symptoms and who has traveled to an area
in which malaria is transmitted. Malaria also should be considered in the differential
diagnosis of persons who have a fever of unknown origin, regardless of their travel
history. Asymptomatic parasitemia can occur among long-term residents of areas in
which malaria is endemic. Untreated P. falciparum infection can progress to coma,
renal failure, pulmonary edema, and death.
During 1993, eight (0.7%) persons who had malaria died. Previously described fac-
tors that may have contributed to these deaths included failure to take the
recommended antimalarial chemoprophylaxis during travel, delay in seeking medical
care, delay in diagnosis and initiation of therapy, and use of suboptimal treatment
regimens (12 ). None of the patients who died during 1993 had taken the appropriate
chemoprophylaxis. Failure to identify and aggressively treat major complications also
may have contributed to some of these deaths.
Treatment for malaria should be initiated immediately after the diagnosis has been
confirmed by a positive blood smear. Treatment should be determined on the basis
of the infecting Plasmodium species, the parasite density, and the patient’s clinical
status (10 ). Although non-falciparum malaria rarely causes severe illness, persons
diagnosed as having P. falciparum infection are at risk for developing severe life-
threatening complications. The use of intravenous quinidine gluconate and exchange
transfusion might be necessary to manage patients who have high levels of para-
sitemia or severe complications (13 ).
Two malaria cases that occurred in New York City were probably locally acquired
from infected Anopheles sp. mosquitoes; these cases represented the seventh out-
break of locally acquired infection in the continental United States during 1989–1993
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(11 ). Local outbreaks were identified twice in San Diego County in 1989 and once in
1990, once in rural Florida in 1990, and twice in suburban New Jersey in 1991 (2–4 ).
The outbreak in 1993 differs from other recent outbreaks in that a) it occurred in an
urban setting and b) the infecting organism was P. falciparum. Health-care providers
should consider malaria in the differential diagnosis of any patient who has an unex-
plained fever, regardless of the patient’s travel history, and they should conduct a
blood smear examination if indicated. To enable prompt investigation of malaria cases
in patients who have not traveled to an area in which malaria is endemic, health-care
providers should immediately notify their state or local health department and CDC of
such cases.
Health-care providers are encouraged to consult appropriate sources for malaria
treatment recommendations or call CDC’s National Center for Infectious Diseases, Di-
vision of Parasitic Diseases at (770) 488-7760 (10 ). Detailed recommendations for
preventing malaria are available 24 hours a day from the CDC Malaria Hotline, which
can be accessed by telephone ([404] 332-4555), facsimile ([404] 332-4565), or CDC’s
World-Wide Web server (http://www.cdc.gov/). CDC annually publishes updated rec-
ommendations in the Health Information for International Travel (9 ), which is
available through the Superintendent of Documents, U.S. Government Printing Office,
Washington, DC 20402-9235; telephone (202) 512-1800.
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APPENDIX
Microscopic Procedures for Diagnosing Malaria
To establish the diagnosis of malaria, a blood smear must be prepared from fresh
finger-prick blood (Figures A-1 and A-2).* The thin smear is fixed in methanol before
staining; the thick smear is stained unfixed. Many hospitals have a Wright-Giemsa
stain available, which is acceptable; however, Wright stain alone will not reliably
stain Plasmodium  parasites. For best results, the smear should be stained with a
3% Giemsa solution (pH of 7.2) for 30–45 minutes. In P. falciparum  infections, the
parasite density should be estimated by counting the percentage of red blood cells
infected—not the number of parasites—under an oil immersion on a thin film. 
Thick blood smears are more sensitive in detecting malaria parasites because the
blood is concentrated, allowing a greater volume of blood to be examined. However,
thick smears are more difficult to read, and thin smears may be preferred by laborato-





Puncture the side of the
ball of the finger. Do not
make the puncture too
close to the nail bed.
If the blood does not
well up from the puncture,
gently squeeze the finger.
Always grasp the
slide by its edges.
To control the size of
the blood drop on the
slide, touch the finger to






FIGURE A-1. Blood collection for thin or thick blood film
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they demonstrate, if stained correctly, blue cytoplasm with a red chromatin dot. Com-
mon errors in reading malaria smears are caused by platelets overlying a red blood
cell, concern about missing a positive slide, and misreading artifacts as parasites. Per-
sons suspected of having malaria but whose blood smears do not demonstrate
the presence of parasites should have blood smears repeated approximately every
12–24 hours for 3 consecutive days. If smears remain negative, then the diagnosis of
malaria is unlikely.
For rapid diagnosis, make the thick and thin films on separate slides. Air dry the
thin film, fix it with methyl alcohol, and immediately stain it. If no parasites are found
on the thin film, wait until the thick film is dry and examine it for organisms that may
not have been detected on the thin preparation.
*In Figures A-1 and A-2, the hands are shown ungloved to better illustrate their placement
during the procedures. However, wearing gloves while processing blood specimens is recom-
mended to prevent transmission of bloodborne pathogens (MMWR 1988;37:377–82, 387–8 and
MMWR 1987;36[no. S2]).
Touch the blood drop
with a clean slide.
Using the corner of
another slide, spread
the blood drop into the
shape of a circle
or square of ~ 1 cm  .3
Gently squeeze the
patient’s finger again,
and touch the edge of a
clean slide to the newly
formed blood drop.
Take this slide and hold the
edge that has the blood
drop at an ~ 45˚ angle
against the surface of the
first slide. Wait until the
blood completely
spreads along the edge
of the second slide.
While holding the second
slide at the same angle,
rapidly and smoothly push
the slide forward.
Write the identification
number on the slide. 











FIGURE A-2. Preparation of a thin and thick blood film on the same slide
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State and Territorial Epidemiologists and Laboratory Directors
State and Territorial Epidemiologists and Laboratory Directors are acknowledged for their contri-
butions to CDC Surveillance Summaries. The epidemiologists listed below were in the positions
shown as of December 1996, and the laboratory directors listed below were in the positions
shown as of December 1996.
State/Territory Epidemiologist Laboratory Director
Alabama John P. Lofgren, MD William J. Callan, PhD
Alaska John P. Middaugh, MD Gregory V. Hayes, DrPH
Arizona Robert W. England, Jr., MD, MPH Barbara J. Erickson, PhD
Arkansas Thomas C. McChesney, DVM Michael G. Foreman
California Stephen H. Waterman, MD, MPH Michael G. Volz, PhD
Colorado Richard E. Hoffman, MD, MPH Robert Quillan, MS, MSPH
Connecticut James L. Hadler, MD, MPH Sanders F. Hawkins, PhD 
Delaware A. LeRoy Hathcock, PhD Chris Zimmerman, MA (Acting)
District of Columbia Martin E. Levy, MD, MPH James B. Thomas, ScD
Florida Richard S. Hopkins, MD, MSPH E. Charles Hartwig, ScD
Georgia Kathleen E. Toomey, MD, MPH Elizabeth A. Franko, DrPH
Hawaii Richard L. Vogt, MD Vernon K. Miyamoto, PhD
Idaho Jesse F. Greenblatt, MD, MPH Richard H. Hudson, PhD
Illinois Byron J. Francis, MD, MPH David F. Carpenter, PhD
Indiana Gregory K. Steele, DrPH, MPH David E. Nauth (Acting)
Iowa M. Patricia Quinlisk, MD, MPH Mary J. R. Gilchrist, PhD
Kansas Gianfranco Pezzino, MD, MPH Roger H. Carlson, PhD
Kentucky Reginald Finger, MD, MPH Thomas E. Maxson, DrPH
Louisiana Louise McFarland, DrPH Henry B. Bradford, Jr, PhD
Maine Kathleen F. Gensheimer, MD, MPH Philip W. Haines, DrPH
Maryland Diane M. Dwyer, MD, MPH J. Mehsen Joseph, PhD
Massachusetts Alfred DeMaria, Jr, MD Ralph J. Timperi, MPH
Michigan Kenneth R. Wilcox, Jr, MD, DrPH Robert Martin, DrPH
Minnesota Michael T. Osterholm, PhD, MPH Pauline Bouchard, JD, MPH
Mississippi Mary Currier, MD, MPH Joe O. Graves, PhD
Missouri H. Denny Donnell, Jr, MD, MPH Eric C. Blank, DrPH
Montana Todd A. Damrow, PhD, MPH Douglas O. Abbott, PhD
Nebraska Thomas J. Safranek, MD John D. Blosser
Nevada Randall L. Todd, DrPH Arthur F. DiSalvo, MD
New Hampshire Vacant Veronica C. Malmberg, MSN
New Jersey Faye Sorhage, DVM, MPH (Acting) Marion Pierce
New Mexico C. Mack Sewell, DrPH, MS Loris W. Hughes, PhD
New York City Benjamin A. Mojica, MD, MPH Alex Ramon, MD, MPH
New York State Perry F. Smith, MD Lawrence S. Sturman, MD, PhD
North Carolina Michael Moser, MD, MPH Lou F. Turner, DrPH
North Dakota Larry A. Shireley, MS, MPH James D. Anders, MPH
Ohio Thomas J. Halpin, MD, MPH Leona Ayers, MD (Acting)
Oklahoma J. Michael Crutcher, MD, MPH (Acting) Garry L. McKee, PhD
Oregon David W. Fleming, MD Michael R. Skeels, PhD, MPH
Pennsylvania James T. Rankin, Jr, DVM, PhD, MPH Bruce Kleger, DrPH
Rhode Island Utpala Bandyopadhyay, MD, MPH Walter S. Combs, PhD
South Carolina James J. Gibson, MD, MPH Harold Dowda, PhD
South Dakota Susan E Lance, DVM, PhD, MPH Vacant
Tennessee William L. Moore, MD Michael W. Kimberly, DrPH
Texas Diane M. Simpson, MD, PhD David L. Maserang, PhD
Utah Craig R. Nichols, MPA Charles D. Brokopp, DrPH
Vermont Peter D. Galbraith, DMD, MPH Burton W. Wilcke, Jr, PhD
Virginia Grayson B. Miller, Jr, MD, MPH James L. Pearson, DrPH
Washington Paul Stehr-Green, DrPH, MPH Jon M. Counts, DrPH
West Virginia Loretta E. Haddy, MA, MS Frank W. Lambert, Jr, DrPH
Wisconsin Jeffrey P. Davis, MD Ronald H. Laessig, PhD
Wyoming Gayle L. Miller, DVM, MPH Roy J. Almeida, DrPH
American Samoa Joseph Tufa, DSM     —
Federated States of
 Micronesia Vacant     —
Guam Robert L. Haddock, DVM, MPH     —
Marshall Islands Tom D. Kijner     —
Northern Mariana Islands Jose L. Chong, MD Isamu J. Abraham, DrPH
Palau Jill McCready, MS, MPH     —
Puerto Rico Carmen C. Deseda, MD, MPH Jose Luis Miranda Arroyo, MD
Virgin Islands Donna M. Green, MD Norbert Mantor, PhD
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